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Of 33 million people living with HIV worldwide in 2015, one-third are estimated to 
be infected with Mycobacterium tuberculosis.1 About 1.2 million new cases of tuberculosis 
(TB) occurred among people living with HIV (PLWH), which account 11% of all TB 
incidence cases.1 HIV-positive pregnant women are a particularly relevant population for 
delivering preventive therapies for HIV and TB. In South Africa, over 30% of women who 
came to public antenatal clinics were HIV-positive in 2013.2 Active tuberculosis during 
pregnancy  increases not only the risk of maternal mortality but also infant adverse health 
outcomes.3–5 Isoniazid preventive therapy (IPT) can reduce the risk of developing TB up to 
60% among PLWH.6 Thus to ensure better health outcomes for both infants and mothers, 
antiretroviral therapy (ART) for life-long period and IPT for at least 12 months are 
recommended to all HIV-positive pregnant women. However, the uptake of IPT has been 
slow around the world and retention in care and adherence rates significantly drop once 
delivery occurs.7,8  
This thesis addresses the gaps in understanding patients’ priorities and motivations to 
take preventive therapies in HIV-positive pregnant women.  In a prospective cohort of 204 
pregnant women recently diagnosed with HIV in Matlosana, South Africa, maternal priorities 
and motivation to take preventive therapies for HIV and TB were examined during the 
 iii 
antepartum and postpartum periods using stated preference methods. Factors at individual, 
interpersonal or health services levels and potential motivators that may influence patients’ 
decisions to take preventive therapies were selected based on qualitative interviews and 
literature reviews. We also explored the cost-effectiveness of providing IPT to all eligible 
HIV-positive pregnant women without LTBI screening strategies.  
Our findings suggest that women prioritize infants’ health and concern for partners 
and family and may make medical decisions around these factors but also have high 
perceived benefits of medications for their own health. Universal IPT could be considered 
cost-effective compared to test-driven strategies. Incorporating these findings would be 
important to develop patient-centered interventions for enhancing the uptake of ART and IPT 
among HIV-positive pregnant women in South Africa and other similar settings with high TB 
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Pregnancy is an important gateway to the health system in South Africa, and during 
the first antenatal care visits many women first learn that they are infected with HIV– a 
diagnosis that can initiate a cascade of medical decisions, including initiation of antiretroviral 
therapy (ART), testing for active and latent tuberculosis (TB), and if infected, isoniazid 
preventive therapy (IPT).  Most women are unprepared for this diagnosis and for the rapid 
flood of healthcare interventions that follow. For ensuring their long-term health and that of 
their babies, it is critical to understand pregnant women’s perception and preferences about 
preventive therapies for HIV and TB and to provide care in a way that is most acceptable to 
these women. The overall aim of this thesis was to examine maternal priorities and 
motivation to take preventive therapies among pregnant women recently diagnosed with HIV 
and to estimate the cost-effectiveness of providing IPT to all eligible HIV-positive pregnant 
women without latent TB infection (LTBI) screening.  This section includes reviews of 
epidemiology of HIV and TB among pregnant women, challenges of uptaking preventive 
therapies and the overall significance of the thesis research.   
 
 2 
1.2 Epidemiology of HIV and TB among pregnant women 
It is estimated that about one-third of the 33 million people living with HIV (PLWH) 
are co-infected with Mycobacterium tuberculosis in 2015.1  There were 1.2 million new cases 
of tuberculosis (TB) among PLWH.1 TB accounts about 25% of all causes mortality among 
PLWH.  The prevalence of HIV infection among adolescent women is 3-7 fold higher than 
among adolescent men in sub-Saharan Africa,9 and women at the age of 15-49 years are at 
the greatest risk of developing active TB disease.10  A study conducted in South Africa 
showed that the prevalence of LTBI among women at reproductive age could be as high as 
84%.11  
Many women first learn that they are infected with HIV during antenatal care (ANC) 
visits. A cross-sectional study in South Africa showed that about 37% of women who came 
to public antenatal clinics were HIV-positive, and of these 23% reported any symptom of TB 
in 2011.12  The prevalence of TB in HIV-positive pregnant women in South Africa is similar 
to that of the general population as 795/100,000 but in some areas, HIV-positive pregnant 
women are at 10-fold increased risk of active TB compared to HIV-uninfected pregnant 
women.5  Tuberculosis increases the risk of maternal mortality during pregnancy or 
postpartum period and infant adverse health outcomes.3–5,13  Thus it is critical not only to 
actively find and treat TB cases but also to prevent conversion of latent TB infection to active 
TB disease.   
 
1.3 Challenge of uptaking preventive therapies   
During the first ANC visit, pregnant women are offered a series of tests including 
HIV counseling and testing, TB symptom screening and a Tuberculin Skin Test (TST) if TST 
is available.14  TST is administered to detect the presence of Mycobacterium tuberculosis, the 
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bacterium that causes TB. Once tuberculin purified protein derivative (PPD) is injected into 
the inner surface of the forearm, the size of induration is measured after 48 to 72 hours to 
determine positivity of reaction. An induration of 5 or more millimeters is considered as 
positive in HIV-positive individuals and other high risk groups.15 
The South African national guideline recommends that if a pregnant woman is newly 
diagnosed with HIV and has active TB symptoms, TB treatment would be started first, 
followed by ART as soon as possible and within 2-8 weeks. All HIV-positive pregnant 
women need to be initiated on a fixed-dose-combination pill (FDC), consisted of three drugs 
used in the first-line regimen (tenofovir, emtricitabine and efavirenz) and continue the 
therapy for a life-long period regardless of CD4 cell count.14  The National TB programme 
(NTP) initially adopted the WHO’s recommendation to provide 6-month IPT to all HIV-
positive persons regardless of TST status in 2010 but re-introduced administration of TST in 
the updated 2014 guideline. Under the new guideline, TST is recommended to determine 
duration of IPT provision: 12 months if TST result is negative or unavailable or 36 months if 
TST is positive. Implementation of this guideline has been slow and challenging partially due 
to operational challenges of TST administration and stock outs of tuberculin.16  
Another challenge is the cascade of HIV care after delivery among pregnant women. 
In a meta-analysis of ART adherence among high, middle and low-income countries, the 
proportion of pregnant women with adequate adherence (defined as taking >80% of pills) 
reduced from 76% during the prenatal period to 53% during the postpartum.17  The initiation 
of and adherence to IPT are even lower.18,19  Only 21% of countries and 14 of the 41 high 
burden TB/HIV countries reported the provision of IPT to HIV-positive people in 2013.20  In 
the prospective cohort conducted in South Africa, 59% of patients who initiated IPT 
completed 6 months of IPT.13 Recent study in Lesotho which evaluated the feasibility of 
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implementation of the IPT guideline in maternal and child health settings showed that 78.5% 
of HIV-positive women initiated IPT, and of whom, 65% completed 6 months of IPT.21  
In the systemic review of qualitative data on factors associated with adherence to IPT 
among people living with HIV/AIDS, five main themes were identified: individual personal 
beliefs, HIV treatment issues, socio-economic factors, family and other social factors, and 
relationship with health providers.22  Work commitment, side effects of isoniazid, HIV-
related stigma as well as non-disclosure of HIV status were reported as the common reasons 
for non-adherence (i.e. defined as completing less than 80% of scheduled clinic visits for 
medicine refill).23  Lack of clear guidance and training on IPT prescription among healthcare 
providers have also been reported as major barriers to implementation of IPT.16      
 
1.4 Overall significance of the research 
Barriers and facilitators of IPT uptake have been explored among patients and 
healthcare providers mostly in qualitative studies.16,22  In this thesis, we examined maternal 
priorities and motivation among different attributes related to taking therapies. 
Implementation of therapies and interventions is often shaped by health care providers, 
researchers and policy makers but not by the patients who actually take the drugs. The 
discrete choice experiment (DCE) is a widely used method to understand how individuals 
may make trade-offs and prioritize among different attributes in decision making.17-20  There 
has been increasing use of DCEs in health service researches to understand patients’ buy-in 
for different therapies or interventions including HIV testing thus to improve patients’ 
adherence and health outcome.24–28  We expect that these results would inform policy makers, 
researchers and healthcare service providers to develop patient-centered strategies for 
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provision of preventive therapies in a way most acceptable to HIV-positive pregnant women 
in South Africa and other similar settings.  
It is also important that IPT provision is implemented in a cost-effective way carefully 
weighting potential benefits and side effects of IPT to be expanded to all eligible HIV-
positive pregnant women. Previous cost-effectiveness analyses of IPT have been mostly 
conducted in high-income and low/middle TB burden countries29,30 and limited studies were 
focused in high TB burden settings.31–34  A recent study in India reported that 6-months IPT 
regardless of CD4 cell counts would be cost-effective compared to IPT provision among 
those with CD4 cell counts <200 cells/mm3 or no IPT at all among HIV-positive pregnant 
women. In South Africa, TST is often used to diagnose latent TB infection but it poses 
operational challenges as tuberculin needs to be refrigerated and patients are required to 
come back for reading the results. Studies have shown that up to 50% of patients may not 
return for TST reading thus losing the opportunity to initiate on IPT.35  On the other hand, 
universally initiating all eligible individuals is subject to put more people without latent TB 
infection into treatment. Thus it is crucial to assess the feasibility and cost-effectiveness of 
providing IPT with and without different LTBI screening strategies in this population.  
  
1.5 Overview of dissertation  
 This dissertation uses the methods and approaches from different disciplines including 
epidemiology and health economics. A total of 204 pregnant women completed the surveys 
to elicit priorities relating to ART and IPT during pregnancy and were followed up at the 14 
weeks postpartum visit. Paper 1 and 2 used a survey instrument of stated preference method 
called best-worst scaling which allowed to elicit the ranking of the relative importance of 11 
attributes related to uptaking ART and IPT. The attributes included treatment benefits for 
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maternal and infant heath, interpersonal support, trust in healthcare services, and structural 
barriers. Paper 3 used a conjoint analysis to understand maternal motivation to take 
preventive therapies. Trust in healthcare providers and medication benefits for having a long 
life were most highly prioritized in both antepartum and postpartum periods (Paper 2). 
Prevention for infants’ illness was slightly more prioritized in the postpartum, and such 
increase in priority was associated with IPT provision at enrollment. However, participants 
expressed significantly greater difficulty in daily adherence to medications in the postpartum. 
When maternal motivation to take preventive therapies was examined, keeping them from 
giving HIV to their partners and keeping them healthy for their family were most prioritized 
in the antepartum but such prioritization decreased in the postpartum (Paper 3). Providing 
IPT all eligible HIV-positive pregnant women can be cost-effective especially if operational 
challenges of latent TB screening strategies prevent people to be initiated for IPT (Paper 4). 
These results suggest that women prioritize infants’ health and concern for partners 
and family and may make medical decisions around these factors in the antepartum period 
but they also have higher perceived benefits for medication for their own health in the 
postpartum. Interventions to reinforce positive benefits of preventive therapies as well as 
counseling and support to encourage adherence can be an effective strategy to increase 








2.1 Study context 
This prospective study was nested within an ongoing randomized study to compare 
the performance of QuantiFERON®-TB In-Tube test (QGIT) to the routine tuberculin skin 
test (TST) in 14 South African clinics for detection of latent TB infection and linkage to 
treatment among individuals newly diagnosed with HIV.36  For the parent study, study 
participants were recruited from 9 clinics located in the Matlosana subdistricts and 5 clinics 
in the Tlokwe subdistrict of the Dr. Kenneth Kaunda district in the North West Province 
(Figure 2.1). There are about 400,000 inhabitants in the City of Matlosana with 41.3% 
residing in Klerksdorp/Jouberton townships.37  Klerksdorp is located approximately 170km 
South West of Johannesburg and has its neighboring township of Jouberton, Stilfontein, 
Orkney, Kanana and Khuma with mix of rural and urban population. The main economic 
activities are mining of gold and platinum group metals and agriculture.  Tlokwe is smaller 
with about 163,000 inhabitants with 128,353 residing in Potchefstroom which hosts five 
tertiary institutions and 30 schools as an academic city. Potchefstroom is located at 45 km 
northeast of Klerksdorp.   
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 The study team was based at the regional office of Perinatal HIV Research Unit 
(PHRU) in the Klerksdorp Tshepong hospital Complex (KTCH), one of the two public sector 
hospitals in the district. Since each clinic has different catchment area for source population, 
we recruited participants from all 14 clinics to have a representative population of these 
regions.  
   
Figure 2.1. The location of 14 clinics in Matlosana and Tlokwe subdistricts in Dr. Kenneth 
Kaunda, North West Province, South Africa.  
 
2.2. Study population and design 
All HIV-positive pregnant women ≥ 18 years of age attending any of the 14 clinics 
between November 2014 and October 2015 were eligible to be enrolled into the study if they 
were newly diagnosed of HIV within 6 months and eligible to receive ART or IPT according 
to the South African guidelines. Since a part of the study questionnaires required participants 
to read written statements, participants who were not able to read a written sample sentence 
were excluded but we offered questionnaires in four most widely used languages in this 
region (English, Setswana, Zulu and Xhosa). We have not included the gestation week as the 
criteria since the timing of 1st ANC visit might be associated with maternal preferences and 
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potentially adherence rate in the postpartum period thus itself is an interest as a research 
question.27 During ANC visits, clinicians referred pregnant women newly diagnosed of HIV 
to study counselors, and eligible pregnant women were consented at a private counseling 
room and enrolled into the study. Each interview lasted for approximately 45 minutes. 
In South Africa, routine postnatal visits for infants and mothers are scheduled at 3 
days, 6, 10, 14 weeks and 4, 5, 6, 9 and 12 months after delivery. We initially proposed to 
conduct two follow-up visits at 6 and 14 weeks postpartum. However, many of the study 
participants presented at either of 6 or 14 weeks visits. Since we expected that delivery itself 
would be the defining event to shape maternal priorities and changes in maternal priorities 
between 6 and 14 weeks might be less significant, we analyzed the data at 14 weeks visit as 
the primary visit and 6 weeks visit or the visit completed after 14 weeks in the postpartum 
was included if participants missed the 14 weeks visit. Characteristics at baseline and follow-
up visits were compared by the type of visits (6, 14 or >14 weeks visits) to ensure 
compatibility across different types of visits.  
During the follow-up visits, maternal and infant clinical information was obtained 
including infant’s HIV status.  The HIV polymerase chain reaction (PCR) test was performed 
at the 6 weeks visit to determine HIV infection status of an infant. The national guideline 
updated in April 2015 recommended to perform HIV PCR tests at 10 weeks, which is four 
weeks after stopping 6-weeks Nevirapine (NVP) prophylaxis.38 Thus all infant HIV status 
was recorded at the 14 weeks postpartum visit. Maternal self-reported adherence to ART and 
IPT was measured by the AIDS Clinical Trials Group (ACTG) Adherence Questionnaire, which 
is based on 4-day recall with five items. This questionnaire has been extensively used and 
validated in other studies.39–42 Adherence to IPT was also measured by testing eligible 
participants’ urine samples by IsoScreen kit (GFC Diagnostics Limited, Oxfordshire, UK), a test 
to measure the presence of INH metabolites over the past 24-48 hours. Maternal priorities and 
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motivations related to preventive therapies were measured at both enrollment and postpartum 
visits using the same stated-preference instruments, which will be explained in the following 
section.         
 
2.2 Assessment of patient preferences and priorities using conjoint analysis and 
best-worst scaling 
 
2.2.1. Definition of patient preferences and application in health research 
Although there may not be a consistent definition, patient preferences can be defined 
as a patient’s value or desirability for health care choices to health state, intervention or 
treatment.43,44  In the field of health service research, methods to quantify preferences can be 
categorized into two ways: 1) indirect elicitation using trade-offs such as ranking, rating, or 
choice designs or 2) direct elicitation of monetary values of an intervention including 
contingent valuation, standard gamble, or willingness-to-pay methods.24  These methods have 
been previously used to understand issues of patient adherence and other health-related 
outcome and applied as alternative sources of utilities.24 The most common types of choice 
designs used to elicit preferences in healthcare research are conjoint analysis, which is often 
referred as discrete choice experiments (DCE)24,  and more recently best-worst scaling (BWS) 
method.45,46  In the following section, detailed theoretical background of these two methods is 
provided. 
  
2.2.2. Theoretical background of best-worst scaling and conjoint analysis 
In economics or marketing research, eliciting an individual’s preferences for goods or 
services can be categorized into two types: 1) revealed preferences, which are examined by 
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observing the actual decisions an individual makes, or 2) stated preferences where an 
individual’s intention for behaviors are elicited in hypothetical situations.47  The most 
common type of conjoint analysis is the discrete choice experiment (DCE), which has been 
widely used in transportation and environmental research to elicit individuals’ preferences 
and predict behaviors.48,49  Recently, DCEs have been applied in health services research for 
various purposes including elicitation of patients’ or providers’ views on diagnosis, treatment 
or access to services. DCEs typically require respondents to make a choice over sets of 
hypothetical alternatives in repeated choice sets (i.e. scenarios) where each alterative is 
described by several characteristics (i.e. attributes). DCEs allow to quantitatively evaluate the 
relative importance of different attributes.50 
 Best-worst scaling (BWS) method was devised by Finn and Louviere (1992) and 
introduced to healthcare research by McIntosh and Louviere (2002).45,51  Unlike in DCEs 
where a respondent need to compare multiple characteristics between two choice sets 
simultaneously, BWS requires each respondent to choose one best and one worst option in a 
given profile. It is assumed that picking up extremes is easier than ranking all alternatives and 
give less cognitive burden compared to DCEs. BWS is grounded on Random Utility Theory 
(RUT), which is based on the assumption that every individual is a rational decision-maker 
thus makes choices to maximize underlying utility within a choice set. The statistical and 
measurement properties of BWS were recently proved although its characteristics still need 
further statistical evidence and rigorous tests.52   
In the random utility model, each person’s choice is comprised of two components, 
the observed characteristics, 𝑣𝑖𝑗, and a stochastic error component, 𝜀𝑖𝑗. Thus utility (𝑢𝑖𝑗) can 
be expressed as following for individual i and attribute j:  
𝑢𝑖𝑗 =  𝑥𝑖𝑗𝛽 + 𝜀𝑖𝑗 = 𝑣𝑖𝑗 + 𝜀𝑖𝑗 
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where 𝑣𝑖𝑗 is the systematic part and 𝜀𝑖𝑗 is the random error term of utility. The main 
assumption of the model is that the 𝜀𝑖𝑗  is iid random variable from Type-I-Extreme-Value 




𝑒−𝜀𝑖𝑗   
 
The random error term cannot be observed for each individual; however, we predict 
the patterns of choices over many individuals and choice occasions, which provide the 
probability Pij of individual i choosing product j from a set of given products as following: 
 
𝑃𝑖𝑗 =  Pr [𝑢𝑖𝑗 > 𝑢𝑖𝑘] = Pr [𝑣𝑖𝑗 + 𝜀𝑖𝑗 > 𝑣𝑖𝑘 + 𝜀𝑖𝑘] 
=  Pr [𝑣𝑖𝑗 − 𝑣𝑖𝑘 +  𝜀𝑖𝑗 > 𝜀𝑖𝑘] for 𝑎𝑙𝑙 𝑘 ≠ 𝑗 
 
If we know 𝜀𝑖𝑗, then we know the choice probability 𝑃𝑖𝑗 is conditional on this 
information. If we rewrite 𝛽𝑘 =  𝑣𝑖𝑗 − 𝑣𝑖𝑘 + 𝜀𝑖𝑗 then the conditional probability,  𝑃𝑖𝑗|𝜀𝑖𝑗 is: 
𝑃𝑖𝑗|𝜀𝑖𝑗  =  Pr [𝜀𝑖𝑘 < 𝛽𝑘 , for  all 𝑘 ≠ 𝑗]  
          =   Pr [𝜀𝑖1 < 𝛽1]  ∙ Pr [𝜀𝑖2 < 𝛽2] ∙ … ∙  Pr [𝜀𝑖𝑗 < 𝛽𝑗, for all 𝑘 ≠ 𝑗 ]  
=    𝑒−𝑒
−𝛽1 ∙  𝑒−𝑒
−𝛽2 ∙ … ∙  𝑒−𝑒
−𝛽𝑗
  




Although we do not know the value of the random error, 𝜀𝑖𝑗, we know that 𝜀𝑖𝑗 follows 
T1EV density. Using Bayes’ Theorem and the known T1EV density function,  
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If we put Q = ∑ 𝑒−(𝑣𝑖𝑗−𝑣𝑖𝑘) 
 𝐽
𝑘=1 and 𝑦 =  𝑒
−𝜀𝑖𝑗, then the choice probability can be 
written as  
𝑃𝑖𝑗 = ∫ 𝑒𝑥𝑝(−𝑦𝑄) ∙ 
∞
0



























            which shows that the probability for an individual i to choose an alternative j follows 
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the logit model for the choice probabilities. When there are more than two alternatives, the 
model follows multinomial logit (often called as conditional logit). Where there are only two 
alternatives, it becomes binary logit and requires key assumption of independent distributions 
of the error terms. The systematic component of utility follows a linear function of 
parameters, resulting in the logit choice probability model as shown above. Thus DCE and 
BWS experiments with two or more options are often analyzed by conditional logistic 
regression in the exploded dataset where each question is treated independently. In 
conditional logistic regression, beta coefficients are estimated using maximum likelihood 
estimation and can be interested as preference or utility weights for given attributes.  
Another assumption of BWS is that the utility of each attribute being chosen as the 
worst attribute is the negative of being chosen as the best attribute. This property was 
mathematically proved by Marley and Lourivere (2005).52  A complete set of best and worst 
choice probabilities on a finite set T satisfies a consistent random utility model provided it 
satisfies a random utility model with a common set of random variables Uz, z  ∈ T, such that 
for 𝑟, 𝑠 ∈ 𝑇, 𝑟 ≠ 𝑠, 𝐵𝑧 = −𝑊𝑍 = 𝑈𝑧 . The probability of maximizing the utility follows the 
standard results of logit formula. There are different assumptions about the process of making 
best and worst choices. The mostly widely accepted assumption is that a respondent chooses 
the best option first, followed by the worst option in a choice set (i.e. sequential best-worst 
model). In this study, I adopted the sequential best-worst model for the analysis.  
Conditional logit assumes that the subjects’ preferences for the attributes and levels 
are homogenous across the population thus the probability of choosing a choice only depends 
on the systematic portion.53  It also assumes that the ratio of probabilities of individuals 
choosing between two alternatives does not depend on the availability or attributes of the 
other attributes, which is referred as the assumption of independence from irrelevant 
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alternatives (IIA). When IIA assumption doesn’t hold, the conditional logit models may 
incorrectly estimate the model outcome. Recently, there have been various approaches to 
relax such assumptions by using a mixed logit (random effects) model or a latent-class model 
or in combination of both methods.54  Unlike in conditional logit where it estimates mean 
preference weights for the study sample, a mixed logit model assumes that there is individual 
heterogeneity and allow coefficients to vary across individuals. Thus the mixed logit model 
measures both mean preference weights and their expected distribution across the sample55 
and provide distributions for both mean preferences weight and standard errors. In Chapter 5, 
the DCE experiment was analyzed using mixed logit models. 
 
2.3 Instrument design and development 
This study adopted the framework suggested for instrument development of a choice 
experiment:1) evidence synthesis, 2) expert consultation, 3) stakeholder engagement, 4) pretest 
interviews, and 5) pilot testing.56  Qualitative interviews were previously conducted as part of 
the parent study, and the results were presented elsewhere.57  Briefly, one male and one female 
participant were recruited from each of the 14 study clinics. In-depth, one-on-one interviews 
were conducted in English by a trained qualitative interviewer in a semi-structured format. 
Interviews lasted approximately one hour and were audio recorded and transcribed. Data 
analysis was carried out using ATLAS.ti 7.0 qualitative data analysis software (Berlin, 
Germany). 
Key ideas were identified and coded using interpretive phenomenological analysis 
(IPA).58  The codes derived from IPA were compared to the case summary findings which 
summarized a given participant’s views and experiences on the key priori domain. The codes 
derived from IPA were classified into four superordinate themes under which three to four 
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subcategories were identified. Other barriers, facilitators or motivations to take preventive 
therapies among HIV-positive pregnant women were additionally identified from literature 
review. The attributes were selected and refined in repetitive process during expert 
consultations. Once the questionnaire was developed, it was pretested among study staff at 
local sites to ensure cultural competency and face validity of the questions. The final 
questionnaire was pilot tested among eligible potential patients at local clinics. We updated 
and refined the questionnaire based on the feedbacks.  
Two types of choice experiments were developed. For paper 1 and paper 2, best-
worst scaling object case (case 1) was used where a total of 11 objects related to preferences 
and characteristics of mothers and infants were elicited based on key informant interviews 
and literature reviews. For paper 3, 2k factorial design was used with seven attributes, each 
attribute with two levels. Since we cannot estimate all 27 combinations, eight combinations 
were generated using design generators in a main-effects orthogonal design to ensure 
statistical independence among the factors.59  Each attribute appeared for an equal number of 
times to minimize the variance in the parameter estimates. More details and examples of 
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The uptake of isoniazid preventive therapy (IPT) has been slow among pregnant 
women living with HIV. We aimed to quantify priorities related to isoniazid preventive 
therapy (IPT) among pregnant women with HIV. We surveyed pregnant women recently 
diagnosed with HIV in 14 South African primary health clinics. Best-worst scaling (BWS) 
was used to elicit the priorities of 11 attributes related to preventive therapies. BWS scores 
were calculated based on the frequency of participants’ selecting each attribute as the best or 
worst among five options (across multiple choice sets) and rescaled from 0 (always selected 
as worst) to 100 (always selected as best). Conditional logit models were used to assess 
differences by IPT status. Among 204 women surveyed, 64 (31%) were receiving IPT at 
enrollment. Trust in healthcare providers was given the highest priority (BWS 
score=73.7±0.9) followed by living a long life (BWS=67.5±0.9). Fear of disclosure of HIV 
serostatus to daily pill-taking was least prioritized (BWS=28.3±0.9). BW scores differed by 
IPT status for a few attributes, but overall ranking of attributes was similar (spearman’s 
rho=0.9). Interventions to build trust in healthcare providers and to emphasize benefits of 





There were 10.4 million new cases and 1.4 million deaths from tuberculosis (TB) 
globally in 2015.1 South Africa in particular has some of the highest rates of HIV and TB 
among pregnant women among whom HIV seroprevalence was about 30% in 2013.2 Active 
TB case finding at antenatal care (ANC) clinics in rural South Africa showed that over 20% 
of HIV-positive pregnant women had at least one symptom of TB at ANC visits.2 TB 
increases maternal mortality during pregnancy and the postpartum period as well as the risk 
of mother-to-child HIV transmission and infant outcomes among HIV-positive women.3,35 
 National Guidelines in South Africa recommend all HIV-positive pregnant women be 
initiated and continued on lifelong antiretroviral therapy (ART) and receive isoniazid 
preventive therapy (IPT) for up to 36 months to reduce TB incidence and mortality.20,60 The 
integration of TB and HIV services in ANC clinics has been strongly promoted in Sub-
Saharan Africa.61 Only 9 of the 30 high-burden TB/HIV countries reported provision of IPT 
in 2015, and the coverage of IPT among people living with HIV (PLWH) is highly variable, 
ranging from 2% to 79%.1 Over-reporting of IPT initiation has been reported in South 
Africa,62 and of those who initiated IPT, the completion rate has been low.18,19 A recent study 
in Lesotho showed that 78.5% of HIV-positive pregnant women initiated IPT, and of these, 
65% completed their six-month course.21 
Several factors are associated with low uptake of IPT among PLWH such as fear of 
side effects, non-disclosure of HIV status or competing socioeconomic responsibilities.23 
Among pregnant women with HIV, earlier gestational age at the first antenatal visit and 
initiation of antiretroviral treatment (ART) were associated with higher rates of IPT 
initiation.21 However, many studies did not report pregnant women as a separate group, and 
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some studies excluded pregnant women altogether. Pregnant women may have different 
priorities and concerns that affect their decision-making related to IPT, and understanding 
their perspectives is important to deliver services in a most acceptable way. We sought to 
quantify the preferences that may encourage or discourage HIV-positive pregnant women to 




3.3.1 Study population and setting 
We recruited HIV-positive pregnant women from 14 primary care public health 
prenatal clinics in the Dr. Kenneth Kaunda health district in the North West province, South 
Africa from January 2015 to December 2015. This study was nested within an ongoing 
cluster randomized trial in the same 14 clinics, which compares proportions with known TB 
infection status and IPT initiation among newly diagnosed HIV patients in clinics using two 
different diagnostic tests for latent TB infection.36,57 Clinics were chosen to cover a range of 
patient volumes, urban vs rural setting, geography and clinic hours. Patients were eligible for 
enrolment if they were ≥18 years old, newly diagnosed with HIV in the preceding six 
months, and able to read either English, Xhosa, Setswana or Zulu. We sought to enroll all 
eligible pregnant patients during the study period. The percentage of enrollment was 
calculated based on the number of eligible patients as reported in the District Health 
Information System (DHIS) between January to July 2015, when the DHIS data was 
available.63 The study was approved by the institutional review boards at the Johns Hopkins 
School of Medicine and University of Witwatersrand. 
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3.3.2 Study design 
We conducted a cross-sectional survey incorporating a best-worst scaling (BWS) 
instrument (Case 1). BWS (Case 1) is a stated-preference method which allows for ranking of 
the relative importance of a list of attributes in a continuous quantitative scale, and has been 
increasingly used in healthcare research to understand patients’ perspectives and 
preferences.64 BWS asks the respondent to choose the best and the worst attribute from a set 
of available options in a given choice task, assuming that participants choose a best-worst 
pair maximizing the difference in the underlying utility.52,56,65,66 
 
3.3.3 Selection of attributes  
Through literature review, and prior in-depth interviews about patients’ experiences 
and perceptions of ART and IPT, which were conducted as part of a qualitative sub-study of 
the parent study,57 we identified attributes likely to influence women’s decision-making 
regarding uptake of preventive therapies.22,23,67 Four different themes were identified: 
treatment benefits for maternal and infant heath, interpersonal support, trust in healthcare 
services, and structural barriers. A total of 11 attributes were chosen, including roughly equal 
numbers of potential barriers and facilitators for initiation of IPT (Table 1). Attributes were 
converted to simple statements, which were then reviewed and refined by clinical experts and 
healthcare providers in the clinics. Identification and refinement of statements followed the 





Table 3.1.  Selected attributes related to preventive therapies tested in the best-worst scaling task 
 
 
3.3.4 Experimental design  
We used a balanced incomplete block design for this study, which allows for 
repetition of different combinations of attributes in the subsets of all possible choice 
scenarios.68 Each respondent was presented with five statements in each given choice task 
and asked to choose one statement out of the five that best described her thoughts, as well as 
the one statement that least described her thoughts. Each of the 11 statements/attributes 
appeared five times across 11 separate choice tasks (Figure 1). The statements/attributes were 
presented in an orthogonal array. To reduce burden, each BWS task was presented 
individually on a flashcard to participants. In addition to BWS tasks, we collected socio-
demographics and brief clinical history from each participant.  
  
Attributes Statements 
Trust in healthcare providers for 
infant’s health 
I trust that doctors and nurses know what is best for infant's health. 
Prevention for infant’s illness Medications I take prevent my infant to get infected or become sick. 
Side effects on infant I worry that if I take pills, it can cause side effects on my infant. 
Strength  Medications to prevent disease help me feel stronger. 
Long life  I can live as long as someone without HIV if I take care of myself. 
Interpersonal support for pill take  Friends and families help me to take medications. 
Fear of unintended disclosure of 
HIV status 
I worry that taking pills every day tells other people that I have HIV. 
Knowledge on pill purpose I know the purpose of each different medication I take. 
Difficulty in daily adherence I have trouble taking medication on a daily basis. 
Travel cost Getting to the clinic costs me too much money. 
Lack of time  I am too busy to come to regular clinic visits. 
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Now I’m going to show you some sets of 5 statements.  For each set, choose the one that BEST 
describes your thought (or the statement you agree with the most), and the one that WORST 
describes your thought (the statement you disagree with the most).  Each new set will have 





Figure 3.1. Example of a best-worst scaling choice task with five attributes related to 
preventive therapies among HIV-positive pregnant women  
 
3.3.5 Data analysis   
The dependent variable was the participants’ choice of best and worst statement in 
each subset of statements presented to them.69  The frequency of being chosen as best and as 
worst over all of the choice tasks was calculated, resulting in a relative BWS score.70  Each 
statement chosen as best received a score of 2 while the statement chosen as worst received a 
score of 0 and all other non-selected statements a score of 1. The aggregate BWS score was 
calculated as the mean score across all respondents, rescaled from 0 to 100. We compared 
BW scores by each woman’s IPT initiation status at the time of enrollment (on IPT at 
enrollment vs. not). We used Spearman’s rho to compare the ranked correlation of the 11 
attributes between the two groups.  
Previous studies have shown that a simple BWS score has good validity compared to 
more sophisticated regression-based methods and good discrimination compared to rating or 
ranking scales.45 We ran conditional logistic regressions and compared the results to BWS 
scores. The coefficients from conditional logistic regressions were compared using Wald 
 
Best Worst 
A. Friends and families help me to take medications.  □ □ 
B. I worry that taking pills every day tells other people that I have HIV.  □ □ 
C. Medications I take prevent my infant to get infected or become sick.  □ □ 
D. Getting to the clinic costs me too much money.  □ □ 
E. I trust that doctors and nurses know what is best for infant's health.  □ □ 
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tests, assuming a null hypothesis of no statistically significant difference by IPT initiation 
status. We also calculated individual BW scores for each statement as above in the scale of 0 
to 2.  Since each statement appeared five times per respondent, the scores for each statement 
ranged from 0 (always selected as worst) to 10 (always selected as best) in each individual. 
The potential association between IPT initiation status and individual BWS scores was 
examined using multivariable linear regression. Initially, multivariable models contained all 
potentially important variables with p-value < 0.20. Then final multivariable models were 
fitted, including only significant individual covariates with p-value < 0.05. All analyses were 
conducted in STATA 13.  
3.4 Results 
3.4.1 Baseline patient characteristics  
A total of 204 pregnant women with HIV were enrolled and completed the 
questionnaire (Table 2). Of these, 31% (n=64) were receiving IPT at time of enrollment. At 
the date of the interview, the mean CD4 count was 469 (±231), and 98% (n=197) were on 
ART. The mean age was 27(±6) years. The mean gestational age at enrollment was 
significantly higher in the IPT group (27±1 weeks) than the no IPT group (24±1 weeks, 
p=0.02). The average time since initial HIV diagnosis was 83±7 days in the IPT group, 
compared to 44±3 days in the no IPT group (p<0.001).  
In the IPT group, 70% (n=45) reported their perceived risk of contracting TB within 
next year as not at all likely while 89% (n=123) in the no IPT group did so (p<0.001). The 
proportion of the study population who was unemployed was high (80%) and did not differ 
by IPT status (p=0.61). About 80% (n=161) of the participants had disclosed their HIV status 
to partners; this percentage did not differ by IPT status (p=0.28). 
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Table 3.2. Baseline characteristics by the current status of Isoniazid Preventive Therapy (IPT) 
among 204 HIV-positive pregnant women, South Africa* 
N (%) 





Age (years), Mean (± SD) 26.9 (±6.5) 27.3 (±5.5) 0.63 
Gestational week at first ANC visit,  
Mean (± SD) 
17.9 (±6.4) 18.1 (± 8.2) 0.91 
Gestational week at enrollment, Mean (± SD)  27.0  (±8.0) 23.5 (±8.8) 0.01 
Time since HIV diagnosis (days), Mean (± SD)  72.5 (±70.9) 43.6 (±41.0) <0.001 
CD4 cell count (cells/mm3), Mean (± SD)‡ 490 (±208) 463 (±239) 0.52 
Perceived risk of developing TB within next year§    
Slightly likely 19 (29.7) 16 (11.5) <0.001 
It is not at all likely 45 (70.3) 123 (88.5)  
Education    
≤ 9 grade 36 (56.2) 69 (49.3) 0.36 
> 9 grade 28 (43.8) 71 (50.7)  
Employment status     
Full time    6 ( 9.4)   18 (12.9) 0.75 
Part time or piece jobs    5 ( 7.8)   12 ( 8.6)  
Unemployed   53 (82.8)  110 (78.6)  
Mode of transportation to clinic    
On foot 35 (54.7) 77 (55.4) 0.98 
Public taxi or bus 27 (42.2) 57 (41.0)  
Private car or motorbike 2 (3.1) 5 (3.6)  
Transportation cost (Rand)    
Median (IQR) 0 (0, 20) 0 (0, 16) 0.17 
Marital status    
Married    8 (12.9)   14 (10.1) 0.09 
Living with partner   22 (35.5)   51 (36.7)  
Not living with partner   26 (41.9)   71 (51.1)  
No current partner    6 (9.7)    3 ( 2.2)  
Disclosure of HIV status to  partner    
Yes   50 (84.8)   111 (81.6) 0.60 
No   9 (15.3)   25 (18.4)  
    
*Pearson 2 test (discrete variables),  t-test (mean comparison for continuous variables) and Mann-Whitney 
test (median comparison for continuous variables) were used. 
†N for on IPT at enrolment and no IPT groups is 48 and 104, respectively.  
‡Some variables have missing data.  
§No one chose other categories of moderately likely, very likely or extremely 
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3.4.2 Attribute prioritization 
Among all participants, trust in healthcare providers for infant’s health was 
prioritized most highly (BWS score=73.7, SE=1.8), followed by having a long life 
(BWS=67.4±1.9) and gaining strength through medications (BWS=61.4±1.6). Fear of 
unintended disclosure of HIV status was prioritized the least (BWS=28.2±1.8), followed by 
medication causing side effects in infants (BWS=33.9±1.8). Lack of interpersonal support for 
taking medications (BWS=42.0±2.0), travel cost (BWS=39.6±1.5), and lack of time 
(BWS=39.2±1.6) had lower BW scores as well.  
When stratified by IPT status, the overall ranking of the attributes was highly 
correlated between the two groups, suggesting the relative (ordinal) importance attached to 
these attributes was strongly correlated (spearman’s rho=0.90).  Those who were currently on 
IPT had a significantly lower BWS score for trust in healthcare providers (BWS=69.3±1.8 vs. 
75.6±1.7, p<0.001) as well as preventive benefits of medications for infant’s health 
(BWS=56.8±1.9 vs. 62.3±1.8, p=0.002) and knowledge of purpose of different medication 
(BWS=57.3±1.5) compared to those who were not on IPT.  Those receiving IPT also had 
significantly higher BW scores for receiving interpersonal support for taking medications 
(BWS=49.2±1.9) compared to those who were not on IPT (BWS=38.8±2.0, p<0.001). The 
rankings from conditional logistic regressions by IPT status were the same as those by BWS 
scores (Supplementary Figure 1).  
In the analyses of the association between individual BWS scores and IPT status, this 
association for interpersonal support persisted, after adjusting for disclosure of HIV status to 
a partner, gestational weeks and number of adults living in the household (p<0.001). IPT 
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status was also associated with a higher individual BWS score for travel cost (0.53±0.20) 
after adjusting for transportation costs and disclosure of HIV status to a partner.  
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Table 3.3. Ranking of 11 statements related to preventive therapies: overall sample and stratified by IPT initiation status during pregnancy  
 Overall Receiving IPT No IPT 
Statement BWS SE BWS SE BWS SE 
I trust that doctors and nurses know what is best for infant's health. 73.7 0.9 69.1 0.9 75.8 0.9 
I can live as long as someone without HIV if I take care of myself. 67.5 0.9 65.2 1.0 68.5 0.9 
Medications to prevent disease help me feel stronger. 61.3 0.8 61.4 0.9 61.3 0.8 
Medications I take prevent my infant to get infected or become sick. 60.7 0.9 56.9 1.0 62.4 0.9 
I know the purpose of each different medication I take. 59.7 0.8 57.2 0.8 60.9 0.8 
I have trouble taking medication on a daily basis. 44.2 0.8 43.7 0.9 44.4 0.8 
Friends and families help me to take medications. 42.0 1.0 49.2 1.0 38.7 1.0 
Getting to the clinic costs me too much money. 39.5 0.7 43.1 0.7 37.9 0.7 
I am too busy to come to regular clinic visits. 39.3 0.8 36.7 0.9 40.4 0.8 
I worry that if I take pills it can cause side effects on my infant. 34.0 0.9 37.7 1.0 32.3 0.9 








Our study findings suggest that pregnant women with a recent HIV diagnosis place a 
higher prioritization on trust with healthcare providers and medication benefits, compared to 
transportation costs or lack of time, when these factors were considered simultaneously.  
BWS methodology has several advantages compared to simple prioritization techniques as it 
reduces cognitive burden and generates more consistent results by allowing only extreme 
choices, rather than ranking or rating all potential options.52 This study of HIV-positive 
pregnant women’s priorities surrounding preventive therapy provides important insight into 
the patient-centered delivery of such therapies in sub-Saharan Africa.  


























      Figure 2. Best-Worst Scaling (BWS) scores for 11 statements related to preventive therapies 
among HIV-positive pregnant women by IPT status. Blue squares represent the mean priority 
score among women receiving IPT at enrollment, while red diamonds represent the responses of 
women not taking IPT. Error bars show 95% confidence intervals, and p-values from Wald tests 




These findings are supported by reports from other qualitative studies showing that 
the perceived patient-derived barriers such as lack of money for transport to clinic or pill 
burden are minor16 and when health care providers gave sufficient information about 
regimens, patients had good level of adherence to IPT.71 Some programmatic interventions 
have evaluated the impact of providing directly observed therapy for IPT or use of lay health 
care workers to support self-supervision on treatment adherence, but such interventions 
resulted in suboptimal completion rates of IPT.72,73 However, patient education and 
counseling increased adherence to TB treatment and IPT by empowering patients, although 
potential effects from these interventions could be dependent on social context and the 
underlying reasons for poor adherence.6,73,74 Our study findings suggest that interventions to 
enhance patients’ knowledge could potentially enhance the uptake of and adherence to 
preventive therapies.  
It may seem contradictory that burden of transportation cost, lack of time or stigma 
from taking daily medications were least prioritized in this study, compared to other studies 
where these were identified as major barriers for uptake of ART and IPT.16,22,75 At least three 
considerations may factor into this counterintuitive result. First, half of the participants in our 
study walked to clinic; thus, the cost of transportation was often low or nonexistent. Second, 
recommended clinic visits for pregnant women are aligned with monthly ART pick-up in 
South Africa, such that any additional transport cost, inconvenience, and stigma related to 
preventive therapy may have been small. Third, women may not be concerned with pill 
burden because nearly all (98%) of our study population were receiving their antiretroviral 
therapy as fixed dose combination tablets, meaning one pill per day.  
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Although we noted some differences in prioritization between women receiving or 
not receiving IPT at enrollment, those differences were relatively minor. Ultimately, the 
overall ranking of statements was similar by IPT status. It is important to note that some of 
the observed differences by IPT status may reflect differences in the corresponding 
populations; for example, those not on IPT reported significantly shorter time since HIV 
diagnosis. Ultimately, our findings suggest that pregnant women’s prioritization of 
statements regarding preventive therapy does not differ according to their previous 
experience in taking IPT.  
 There are several limitations in this study. First, we asked participants to choose 
between statements with both positive and negative connotations in the same choice task. 
Therefore, our results can only infer which statements were perceived as best, and which 
were perceived as worst. Future efforts could expand on this work by elucidating the degree 
to which positive statements refer to facilitators of preventive therapy, and negative 
statements refer to barriers. Second, recruitment of participants was logistically difficult.  
Based on the DHIS data in South Africa, we estimate about 40% of eligible women could not 
be recruited for this study, despite vigorous efforts to enroll all eligible women. We used 
three interviewers to rotate through all14 clinics for recruitment, which limited our capacity 
to enroll all eligible women presenting at ANC visits. Third, our methods assume that the 
importance assigned to the best or worst statement is similar across individuals. We are 
therefore unable to assess whether specific individuals might prioritize a particular statement 
much higher, or much lower, than others. Approaches such as scale-adjusted latent class or 
segmentation may be more appropriate to explore potential heterogeneity in priorities across 
individuals and develop targeted interventions in future. Finally, we caution that our results 
comparing priorities by IPT status were not intended to reveal a causal relationship and 
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should not be interpreted as such. Future studies to elicit preferences in a longitudinal design 
are warranted.  
  We have quantified the priorities stated by HIV-positive pregnant women in South 
Africa across statements related to preventive therapy. We demonstrate that trust in 
healthcare providers and living a long life are prioritized positively, while fear of HIV 
disclosure is prioritized the least. These findings illustrate the importance of eliciting and 
responding to patients’ priorities when attempting to implement interventions that seek to 
prevent future disease, including IPT. Our results can help to design effective patient-
centered approaches to IPT delivery among pregnant women with HIV, with the ultimate 
goal of improving the health of this key population.  
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Supplementary Table 3.1. Coefficients and standard errors (SE) from conditional (fixed-effects) logistic regression for 11 statements 
related to preventive therapies: overall sample and stratified by IPT initiation status during pregnancy 
  Overall  Receiving IPT No IPT   
Statement Coefficients SE Coefficients SE Coefficients SE 
P-
value* 
I trust that doctors and nurses know what is best for infant's health. 1.519 0.057 1.134 0.104 1.703 0.076 <0.001 
I can live as long as someone without HIV if I take care of myself. 1.158 0.057 0.897 0.105 1.309 0.075 <0.01 
Medications to prevent disease help me feel stronger. 0.775 0.057 0.748 0.103 0.816 0.076 0.59 
Medications I take prevent my infant to get infected or become sick. 0.671 0.057 0.358 0.105 0.893 0.076 <0.001 
I know the purpose of each different medication I take. 0.598 0.057 0.411 0.104 0.697 0.075 0.03 
I have trouble taking medication on a daily basis. -0.404 0.056 -0.416 0.102 -0.417 0.074 1.00 
Friends and families help me to take medications. -0.602 0.058 -0.135 0.107 -0.923 0.076 <0.001 
Getting to the clinic costs me too much money. -0.655 0.055 -0.336 0.101 -0.843 0.073 <0.01 
I am too busy to come to regular clinic visits. -0.691 0.056 -0.818 0.101 -0.638 0.075 0.15 
I worry that if I take pills, it can cause side effects on my infant. -1.006 0.056 -0.700 0.102 -1.113 0.074 <0.01 
I worry that taking pills every day tells other people that I have HIV. -1.363 0.051  -1.143 0.093 -1.484 0.068  <0.01 




   



























Supplementary Figure 3.1. Coefficients from conditional logistic regressions for 11 statements related to preventive therapies among HIV-
positive pregnant women by IPT status. Blue squares represent the regression coefficients among women receiving IPT at enrollment, 
while red diamonds represent the regression coefficients among not taking IPT. Error bars show 95% confidence intervals, and p-values 
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 Pregnant women newly diagnosed of HIV during pregnancy is often lost to follow up 
after delivery. We aimed to quantify changes in priorities related to isoniazid preventive therapy 
(IPT) and antiretroviral therapy (ART) among pregnant women newly diagnosed of HIV in the 
ante- and postpartum periods.  We surveyed pregnant women recently diagnosed with HIV in 14 
primary health clinics at enrollment and 14 weeks after delivery in Matlosana, South Africa. Best-
worst scaling (BWS) was used to elicit the priorities of 11 attributes related to preventive 
therapies. Aggregate BWS scores were calculated based on the frequency of participants’ 
selecting each attribute as the best or worst among five options across multiple choice sets. 
Individual BWS scores were also calculated and rescaled from 0 (always selected as worst) to 10 
(always selected as best), and the changes in BWS scores during the ante- vs postpartum periods 
were compared using a paired t-test. Factors associated with the changes in BWS scores were 
examined in multiple linear regressions. Spearman’s rho was used to compare the ranking of 
attributes in the ante- vs. postpartum.  
Among 204 women surveyed, 154 (75.5%) completed the postpartum visits at the median 
time of 106 days (IQR 75-190) after delivery. Trust in healthcare providers was most highly 
prioritized both in the ante- (individual BWS Score=7.34, SE=0.13) and postpartum periods 
(BWS=7.21±0.11). Prevention for infants’ health was more highly prioritized in the post- 
(BWS=6.54±0.09) vs. antepartum (BWS=6.11± 0.10) (p=0.05), which was associated with IPT 
initiation at enrollment (regression coefficient=0.78 ± 0.33, p=0.001). Difficulty in daily pill-
uptake had significantly higher priority in the postpartum (BWS=5.03±0.11) than in the 
antepartum (BWS=4.43±0.10) (p<0.01). Overall ranking of attributes was similar at both time 
periods (spearman’s rho=0.90). IPT provision may enhance HIV-positive pregnant women’s 
perceptions for benefits of preventive therapies but interventions to support adherence and build 
trust in healthcare providers may be needed to increase IPT uptake.  
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4.2 Introduction  
There were 10.4 million new cases and 1.4 million deaths from tuberculosis (TB) 
globally in 2015.1  Over 50% of TB cases are co-infected with HIV in South Africa, and TB is the 
leading cause of mortality among HIV-positive individuals.76  South Africa has some of the 
highest rates of HIV and TB among pregnant women whose HIV seroprevalence was about 30% 
in 2013.2  TB increases maternal mortality during pregnancy and the postpartum period as well as 
the risk of mother-to-child HIV transmission and adverse infant outcomes among HIV-positive 
women.3,4,35  Thus preventing maternal TB is crucial to ensure the health for both mothers and 
their infants. Active TB case finding at antenatal care (ANC) clinics in rural South Africa showed 
that over 20% of HIV-positive pregnant women had at least one symptom of TB at ANC visits.2  
The national guideline in South Africa recommends that pregnant women diagnosed with 
HIV are to initiate lifelong antiretroviral therapy (ART) and receive isoniazid preventive therapy 
(IPT), a daily provision of isoniazid (INH) for up to 36 months to reduce TB incidence and 
mortality,20,60  yet many women may not be prepared for these long-term commitment.  In sub-
Saharan Africa, loss to follow-up (LFU) after delivery among pregnant women diagnosed with 
HIV can be high as 50%.8  Adherence rates to ART and IPT also significantly drop after delivery. 
In a meta-analysis, the proportion of women with adequate adherence for ART (>80%) reduced 
from 76% during the prenatal period to 53% during postpartum.17  A recent study in Lesotho 
showed that 78.5% of HIV-positive pregnant women initiated IPT, and of these, 65% completed 
their six-month courses.21 
Several factors are associated with low uptake of IPT among PLWH, such as fear of side 
effects, non-disclosure of HIV status, and competing socioeconomic responsibilities.23 Other 
competing risks including relocation,  returning to work, and HIV-related social stigma have been 
reported as factors for LFU and ART discontinuation in the postpartum period, increasing 
likelihood of failing viral load suppression.77–79  Previous qualitative studies among HIV-positive 
  
 38 
pregnant women have shown that perceived benefits of ART as “life-giving” as well as treatment 
support from healthcare workers were important factors.80,81  Understanding changes in pregnant 
women’s priorities before and after delivery is crucial to deliver services in a most acceptable 
way to these women. In this study, we sought to quantify the preferences that may encourage or 
discourage HIV-positive pregnant women’s uptake of preventive therapies and engagement in 
care.   
 
4.3 Methods 
4.3.1 Study population and setting 
 This study was conducted in 14 primary healthcare clinics in Klerksdorp and 
Potchefstroom, Dr. Kenneth Kaunda District in the North West Province of South Africa. We 
recruited HIV-positive pregnant women from 14 primary care public health clinics (PHC) in the 
Dr. Kenneth Kaunda health district in the North West province, South Africa from February 2015 
to February 2016. This study was nested within an ongoing cluster randomized trial in the same 
14 clinics, which compares proportions with known TB infection status and IPT initiation among 
newly diagnosed HIV patients in clinics using two different diagnostic tests for latent TB 
infection.36,57  Of a total of 24 PHCs from Matlosana and Tlokwe subdistricts, 14 PHC were 
selected to be included for TEKO substudy to cover a range of patient volumes, urban vs rural 
setting, geography and clinic hours.  
Patients were eligible for enrollment if they were ≥18 years old, newly diagnosed with 
HIV in the preceding six months, and able to read one of the following languages: English, 
Xhosa, Setswana or Zulu. We sought to enroll all eligible pregnant patients during the study 
period, and the percentage of enrollment was calculated based on the number of eligible patients 
reported in the District Health Information System (DHIS) between January 2015 and July 2015, 
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when the DHIS data was available.63  Written informed consents were obtained from all 
participants. The study was approved by the institutional review boards at the Johns Hopkins 
School of Medicine and University of Witwatersrand.  
 
4.3.2 Study design 
We conducted a longitudinal survey incorporating a best-worst scaling (BWS) instrument 
(Case 1) from January 2015 to September 2016. All pregnant women were enrolled during 
pregnancy and completed one follow-up visit at the 14 weeks postpartum.  BWS (Case 1) is a 
stated-preference method which allows for ranking of the relative importance of a list of attributes 
in a continuous quantitative scale and has been increasingly used in healthcare research to 
understand patients’ perspectives and preferences.64 Each respondent chooses the best and the 
worst attribute from a set of available options in a given choice task, assuming that participants 
choose a best-worst pair maximizing the difference in the underlying utility.52,56,65,66  
 
4.3.3 Selection of attributes  
We identified attributes likely to influence women’s decision-making regarding uptake of 
preventive therapies through literature review and prior in-depth interviews about patients’ 
experiences and perceptions of ART and IPT, which focused on the participants' general 
perceptions of healthcare services, their understanding of TB, experience and views on IPT, and 
barriers and facilitators of medication adherence.57,22,23,67  Four themes were ascertained: 
treatment benefits for maternal and infant heath, interpersonal support, trust in healthcare 
services, and structural barriers. A total of 11 attributes were chosen, including roughly equal 
numbers of potential barriers and facilitators for initiation of IPT (Table 1). Attributes were 
converted to simple statements, which were then reviewed and refined by clinical experts and 
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healthcare providers in the clinics. Identification and refinement of statements followed the 
framework for instrument development of a choice experiment.56  
 
Table 4.1. 11 Selected attributes related to preventive therapies tested in the best-worst scaling 
task 
Attributes Statements 
Trust in healthcare providers for 
infants’ health 
I trust that doctors and nurses know what is best for infant's health. 
Prevention for infant’s illness Medications I take prevent my infant to get infected or become sick. 
Side effects on infant I worry that if I take pills, it can cause side effects on my infant. 
Strength  Medications to prevent disease help me feel stronger. 
Long life  I can live as long as someone without HIV if I take care of myself. 
Interpersonal support for pill 
take  
Friends and families help me to take medications. 
Fear of unintended disclosure of 
HI status 
I worry that taking pills every day tells other people that I have HIV. 
Knowledge on pill purpose I know the purpose of each different medication I take. 
Difficulty in daily adherence I have trouble taking medication on a daily basis. 
Travel cost Getting to the clinic costs me too much money. 
Lack of time  I am too busy to come to regular clinic visits. 
 
 
4.3.4 Experimental design  
We used a balanced incomplete block design for this study, which allows for 
repetition of different combinations of attributes in the subsets of all possible choice 
scenarios.68  Each respondent was presented with five statements in each given choice task 
and asked to choose one statement out of the five that best described her thoughts, as well as 
the one statement that least described her thoughts. Each of the 11 statements/attributes 
appeared five times across 11 separate choice tasks (Figure 4.1). The statements/attributes 
were presented in an orthogonal array. To reduce burden, each BWS task was presented 
individually on a flashcard to participants.   
  
 41 
Now I’m going to show you some sets of 5 statements.  For each set, choose the one that 
BEST describes your thought (or the statement you agree with the most), and the one that 
WORST describes your thought (the statement you disagree with the most).  Each new set will 






Figure 4.1. Example of a best-worst scaling choice task with five attributes related to 
preventive therapies among HIV-positive pregnant women  
 
4.3.5 Sociodemographic, clinical variables and adherence measurement 
Participants’ sociodemographic and clinical information was obtained at enrollment. 
Details related to delivery and history of breastfeeding were obtained in the postpartum visit. 
Infant HIV status and clinical information were collected if the HIV polymerase chain reaction 
(PCR) test results were available. Participants were also asked about the degree of support 
received from healthcare workers, family or friends to take medications and whether they were 
satisfied with the support. Self-reported adherence rates were measured by the AIDS Clinical 
Trials Group (ACTG) Adherence Questionnaire, which is based on 4-day recall with five items. 
This questionnaire has been extensively used and validated in other studies.39–42  Being adherent 
to ART or IPT was defined as taking all drugs in the previous 4 days. Adherence to IPT was also 
measured by testing eligible participants’ urine samples by IsoScreen kit (GFC Diagnostics 
Limited, Oxfordshire, UK), a test to measure the presence of INH metabolites over the past 24-48 
hours. Black/violet color indicates that the patient has taken a INH within 1 day; green color 
indicates taking it within 2 days; and yellow means no INH taken within 2 days. There is no 
 
Best Worst 
A. Friends and families help me to take medications.  □ □ 
B. I worry that taking pills every day tells other people that I have HIV.  □ □ 
C. Medications I take prevent my infant to get infected or become sick.  □ □ 
D. Getting to the clinic costs me too much money.  □ □ 
E. I trust that doctors and nurses know what is best for infant's health.  □ □ 
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routine test for INH or monitoring for IPT at the study sites so IsoScreen kit was performed by 
trained study interviewers.  
 
4.3.6 Data analysis   
The outcome was the participants’ choice of best and worst statement in each subset 
of statements presented to them in the ante- and postpartum.69  The frequency of best and 
worst statement choices across all choice tasks was calculated, resulting in a relative BWS 
score.70  Each statement chosen as best received a score of 2 while the statement chosen as 
worst received a score of 0 and all other non-selected statements a score of 1. The aggregate 
BWS score was calculated as the mean score across all respondents, rescaled from 0 to 100. 
Previous studies have shown that a simple BWS score has good validity, compared to more 
sophisticated regression-based methodsand good discrimination compared to rating or 
ranking scales.45  Conditional logistic regression models were fitted and compared to BWS 
scores. The coefficients from conditional logistic regression models were compared using 
Wald tests under the null hypothesis that there is no statistically significant different in BWS 
scores in the antepartum vs. postpartum.  
We also calculated individual BWS scores for each statement as above in the scale of 
0 to 2 in the antepartum and postpartum, separately. Since each statement appeared five times 
per respondent, the scores for each statement ranged from 0 (always selected as worst) to 10 
(always selected as best). The difference in the antepartum vs. the postpartum was calculated 
and compared using paired t-test. We examined the potential association between individual 
BWS scores and other factors in multivariable linear regression. Initially, multivariable 
conditional logistic regression models contained all potentially important variables with p-
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value < 0.20. Then final multivariable conditional logistic regression models were fitted, 
including only significant individual covariates with p-value < 0.05. All analyses were 
conducted in STATA 13.  
 
4.4 Results 
4.4.1 Patient characteristics  
Of 204 pregnant women who were enrolled during pregnancy, 47 did not complete 
the follow-up visits. Of these 27 participants lost to follow up, 20 (42.6%) were relocated to 
out of the study area, 23 (49.9%) were contacted three times but could not be reached, and 4 
lost interest in the study or refused to participate further. The baseline characteristics were 
similar among those who were lost to follow up and those included in the analysis. Of 155 
(75.6%) who had at least one follow-up visit, 77 (49.7%) were followed at 14 week visit, 33 
(21.3%) at 6 weeks visit and 45 (29.0%) at later than 14 weeks after delivery. The mean time 
since delivery at follow-up visits was 15 (IQR: 11-27) weeks.  
About thirty percent (n=45) were receiving IPT while 98% (n=151) were on ART at 
enrollment (Table 4.2). The mean age was 27(±6) years with the mean gestational age at 
26(±1) weeks at enrollment. The mean CD4 cell count was 457 (±242) cells/mm3 with the 
average time since initial HIV diagnosis of 55±52 days. The unemployment rate was high 
(>80%). About 80% (n=125) of the participants had disclosed their HIV status to their 
partners, and 39 participants (19.5%) reported that they planned to stay with family in home 
resident after delivery. 
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In the postpartum, of 155 participants, 2 (1.3%) infants were found to be HIV-
positive; 125 (89.3%) had negative HIV status and 13 (8.4%) had unknown HIV status. 
There were 10 (6.5%) participants with incomplete data on infant HIV status. Near 90% 
(n=132) of participants ever breastfed their infants, and 57% (n=88) was still breastfeeding.  
4 (5.4%) reported that they experienced a stock-out problem at the clinic for IPT or ART in 
the last 12 months. While 49.4% reported that they received somewhat or a lot of support 
from friends and family to remember taking medications, 88.4% (n=137) did so from 
healthcare providers (p<0.001). About 95% people of patients who were on ART reported 
that they were informed about side effect and reasons to take ART while 89.3% of people 
who were on IPT did so.    
Of 36 participants who had follow-up visits completed within 12 months since the 
date of IPT initiation, 9 (25%) were still prescribed to take IPT, and the results of IsoScreen 
kit are following: 4 black/violet (INH taken within 1 day), 1 green (INH taken within 2 days) 
and 2 yellow (no INH taken within 2 days). All of these participants reported being adherent 
to IPT based on self-reported adherence measure. Additionally, 18 were initiated on IPT after 
study enrollment. Of these, 13 out of 14 (92.8%) were adherent to IPT based on self-reported 
adherence and matched with IsoScreen results for being adherent (81.8%, n=9). For ART, 
everyone reported taking ART in the postpartum visits; of 145 who completed the adherence 





Table 4.2. Baseline characteristics and follow-up variables by the status of Isoniazid Preventive 
Therapy (IPT) at enrollment among 154 HIV-positive pregnant women, South Africa* 
N (%) 






Age (years), Mean (± SD) 27.5 (± 6.4) 27.4 (± 5.6) 0.89 
Gestational week at first ANC visit,  
Mean (± SD) 
18.6 (±6.2) 18.1 (±8.2) 0.70 
Gestational week at enrollment, Mean (± SD)  27.0  (±7.4) 23.8 (±9.1) 0.05 
Time since HIV diagnosis (days), Mean (± SD)  77.9 (±67.7) 44.9 (±41.4) <0.001 
CD4 cell count (cells/mm3), Mean (± SD)** 481 (±227) 467 (±248) 0.79 
Perceived risk of developing TB within next 
year*** 
   
Slightly likely   16 (35.6)   12 (11.1) <0.001 
It is not at all likely   29 (64.4)   96 (88.9)  
Education**    
≤ 9 grade    9 (25.0)   21 (26.9) 0.83 
> 9 grade   27 (75.0)   57 (73.1)  
Employment status     
Full time    2 ( 4.4)   11 (10.1) 0.35 
Part time or piece jobs    5 (11.1)    7 ( 6.4)  
Unemployed   38 (84.4)   91 (83.5)  
Mode of transportation to clinic    
On foot   23 (51.1)   61 (56.0) 0.86 
Public taxi or bus   21 (46.7)   46 (42.2)  
Private car or motorbike    1 ( 2.2)    2 ( 1.8)  
Transportation cost (Rand)    
Median (IQR) 0 (0, 20) 0 (0, 16) 0.14 
Marital status    
Married    7 (18.4)   10 (9.3) 0.31 
Living with partner   13 (34.2)   39 (36.1)  
Not living with partner   18 (47.4)   59 (54.6)  
Disclosure of HIV status to  partner    
Yes   28 (62.2)   54 (50.5) 0.18 
No   17 (37.8)   53 (49.5)  
*Pearson 2 test (discrete variables),  t-test (mean comparison for continuous variables) and Mann-Whitney 
test (median comparison for continuous variables) were used. 
**Some variables have missing data.  
***No one chose other categories of moderately likely, very likely or extremely likely. 
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4.4.2 Aggregate BWS scores in the antepartum and postpartum  
Trust in healthcare providers was prioritized most highly in the postpartum (BWS 
=72.1, SE=2.6), followed by having a long life (BWS=68.6±2.5), and they did not 
significantly differ from the antepartum (Table 4.3). Prevention of infants’ illness had 
significantly higher scores in the postpartum (BWS=65.4±2.4) than in the antepartum 
(BWS=61.1±2.2) (p<0.01).  Difficulty in daily medication adherence was also significantly 
more prioritized in the postpartum (BWS=50.3± 1.8) than in the antepartum (BWS=44.3±1.6) 
(p<0.001). Travel cost (p<0.01) and side effects for infants (BWS=28.4±1.0 vs. 33.6±1) 





Table 4.3. Frequency of attributes chosen among 11 statements and aggregate BWS scores in the antepartum vs. postpartum (N=154) 
11 Statements 











I trust that doctors and nurses know what is best for 
infant's health. 
387 27 73.4 2.6  361 20 72.1 2.6 0.38 
I can live as long as someone without HIV if I take 
care of myself. 
324 51 67.7 2.4  306 19 68.6 2.5 0.53 
Medications I take prevent my infant to get infected or 
become sick. 
241 70 61.1 2.2  265 28 65.4 2.4 <0.01 
Medications to prevent disease help me feel stronger. 213 45 60.9 2.2  148 20 58.3 2.1 0.04 
I know the purpose of each different medication I take. 201 34 60.8 2.2  227 19 63.5 2.3 0.04 
I have trouble taking medication on a daily basis. 70 157 44.3 1.6  104 100 50.3 1.8 <0.001 
Friends and families help me to take medications. 117 243 41.7 1.5  98 266 38.9 1.4 0.1 
I am too busy to come to regular clinic visits. 45 197 40.1 1.4  69 154 44.5 1.6 <0.01 
Getting to the clinic costs me too much money. 25 195 39.0 1.4  16 244 35.2 1.3 <0.01 
I worry that if I take pills  it can cause side effects on 
my infant. 
38 290 33.6 1.2  18 350 28.4 1.0 <0.001 
I worry that taking pills every day tells other people 
that I have HIV. 
27 376 27.3 1.0  43 435 24.5 0.9 0.06 
 
*Number of times chosen as best attribute in a given choice set is calculated. A total of 770 (154 respondents x 5 times per attribute) was available to be 
selected per attribute.  




4.4.3 Changes in individual BWS scores in the antepartum vs. postpartum  
When individual BWS scores were compared in the antepartum vs. postpartum, we 
observed similar patterns of prioritization (Table 4.4). Trust in healthcare providers for 
infants’ health was prioritized most highly both in the ante- (BWS=7.2, SE=0.1) and the 
postpartum (BWS=7.3±0.1), and these did not significantly differ (p=0.46) (Figure 4.2). 
Having a long life was similarly prioritized in the ante- (BWS=6.8±0.1) and postpartum 
(BWS=6.9±0.1) (p=0.56). Compared to the antepartum, prevention for infants’ health was 
slightly more prioritized in the postpartum (p=0.05) as well as difficulty in daily pill-take 
(p<0.01) and lack of time to come to regular clinic visits (p=0.01). Fear of unintended 
disclosure of HIV status was least prioritized in both antepartum vs. postpartum 
(BWS=2.7±0.1 vs. 2.5±0.2, p=0.19), followed by medication causing side effects in infants 
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Figure 4.2. Changes in individual Best-Worst Scaling (BWS) scores for 11 statements related to preventive therapies among HIV-positive 
pregnant women in the postpartum vs. antepartum periods. Error bars show 95% confidence intervals, and p-values from Wald tests 

























*P-values were calculated from Wald tests comparing mean BWS scores by timing of visits.  
 
 
 Antepartum Postpartum Difference  
Statement 
Mean  SE Mean  SE Mean  SE 
p-
value* 
I trust that doctors and nurses know what is best for infant's health. 7.34 0.13 7.21 0.11 0.12 0.17 0.46 
I can live as long as someone without HIV if I take care of myself. 6.77 0.13 6.86 0.1 -0.09 0.16 0.56 
Medications I take prevent my infant to get infected or become sick. 6.11 0.12 6.54 0.09 -0.43 0.15 0.01 
Medications to prevent disease help me feel stronger. 6.09 0.1 5.83 0.07 0.26 0.13 0.05 
I know the purpose of each different medication I take. 6.08 0.11 6.35 0.1 -0.27 0.14 0.06 
I have trouble taking medication on a daily basis. 4.43 0.1 5.03 0.11 -0.59 0.14 <0.01 
Friends and families help me to take medications. 4.17 0.17 3.89 0.17 0.27 0.23 0.23 
I am too busy to come to regular clinic visits. 4.01 0.12 4.45 0.14 -0.44 0.17 0.01 
Getting to the clinic costs me too much money. 3.9 0.11 3.52 0.09 0.38 0.14 0.01 
I worry that if I take pills  it can cause side effects on my infant. 3.36 0.12 2.84 0.1 0.52 0.16 <0.01 
I worry that taking pills every day tells other people that I have HIV. 2.73 0.14 2.45 0.18 0.28 0.21 0.19 
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4.4.4 Association between changes in individual BWS scores and other factors    
Several factors were examined for the association with changes in the individual 
BWS scores in the antepartum vs. postpartum using multiple regression. Being married was 
significantly associated with a higher individual BWS score for difficulty in daily pill-take in 
the postpartum (coefficient (ß)=0.72±0.28, p=0.01). Lack of time to come to regular clinic 
visits was associated with the decrease in the individual BWS scores in the postpartum (ß=-
0.82±0.35, p=0.02).  
IPT initiation at enrollment was associated with significantly higher individual BWS 
scores for prevention for infants’ health (ß=1.09±0.32, p=0.001) after adjusting for TB 
treatment history and number of previous pregnancy. It was also associated with decrease in 
the BWS scores for side effects on infants (ß=-0.87±0.35, p=0.02) and interpersonal support 
from families and friends (ß=-1.61±0.50, p=0.001). Being adherent to ART was significantly 
associated with higher BWS score for living a long life (ß=1.71±0.65, p=0.01).  
 
4.5 Discussion  
Pregnant women newly diagnosed with HIV antepartum face the decision of starting 
lifelong ART, and this decision is often prioritized around infants’ health. Our study findings 
suggest that pregnant women with a recent HIV diagnosis receiving ART highly prioritize 
trust with healthcare providers and prevention of infants’ illness, and these preferences 
persist after delivery. In the postpartum, women consistently showed high prioritization on 
having a long life and perceived medication benefit for their own health, and barriers such as 
lack of time or high transportation cost to come to regular clinic visits were less prioritized. 
Interestingly, those who had initiated IPT during pregnancy were more likely to perceive the 
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benefits of medications on infant’s health in the postpartum period. This may be supported 
that almost everyone (96.4%) who received IPT reported that clinical staffs told them the 
purpose of IPT during the last clinic visit. The statement of knowing the purpose of different 
medications was also highly perceived, suggesting that women in the postpartum are aware 
of the benefits of ART and IPT for both their own and infants’ health. Lack of time to come 
to regular clinic visits was more prioritized in the postpartum period, potentially reflecting 
the impact of life-changing event of having a newborn baby.  
Earlier studies documented that HIV-positive women are less likely retained in care 
and adherence rates to ART drop in the postpartum. 7,8,17 Mothers could be less motivated to 
take preventive therapies and seek HIV cares once they had protected their infants from HIV 
transmission and successfully weaned them.82 Other reasons were reported as feeling well, 
demands of everyday life or HIV-related stigma. 7,8,17  In this study, even in the postpartum 
period and after weaning, mothers highly prioritized medication benefits for their own health.   
In our study, most participants were taking one pill of fixed-dose combination (FDC) 
and one daily isoniazid pill under IPT. The self-reported adherence to ART was very high as 
> 90% although more objective measurement like viral suppression was not available and the 
high self-reported adherence rate could have been overstated.82,83  IPT prescription at 
enrollment was low at around 30%, and the duration of IPT prescription could not be 
obtained from patients’ medical charts for most of participants. Of those who were receiving 
IPT at enrollment and in the postpartum, the proportion of people adhering to IPT was sub-
optimal based on the results of IsoScreen kit although our sample size may be too small to 
detect any significant difference in level of adherence to IPT. More participants reported that 
they had trouble taking medication on a daily basis in the postpartum. Counseling and 
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interventions to address challenges related to adherence may enhance IPT uptake in the 
postpartum.   
Our study has some contradictory finding to previous studies. Previous study showed 
that patients may be concerned about the side effects of IPT and be less likely to complete the 
treatment.84 We found that mothers were consistently least concerned about side effects that 
the treatment may impact on infants; rather, benefits of preventive therapies for both infants 
and maternal health were highly prioritized over side effects.  
Trust in healthcare providers was highly perceived. About 90% of study participants 
reported that they received help from clinical staff to remember taking medications. Other 
studies have shown that patients could have good adherence to IPT and retention in care if 
they were informed about the benefits of the drugs, 71  and patient education and counseling 
increased adherence to TB treatment and IPT by empowering patients.6,73,74  Contrary to the 
high proportion of participants receiving support from clinical staff, half of participants 
reported that they received little or no support from friends and family to remember taking 
medications in the postpartum. In the qualitative interviews conducted in the same 14 study 
clinics in South Africa, family was mentioned as a common and importance source of 
support.57  Having a supportive system is vital for retention in care and adherence to ART 
and IPT among HIV-positive individuals,67 especially among postpartum women.85  The 
follow-up period of this study was relatively short and the sample size was quite small thus 
we could not ascertain the impact of lack of support from family and friends on the long term 
health outcomes. More comprehensive package of care would be needed to inform and 
engage family members in this setting.  
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 This is one of the first studies to use a choice experiment in understanding maternal 
priorities to preventive therapies around the time of delivery among HIV-positive pregnant 
women. We demonstrated that a choice experiment such as BWS can be used as an 
alternative to quantitative rating or ranking scales. BWS experiment has a particular strength 
to discriminate among attributes.45 It also allows to compare attributes from different 
domains from individual to interpersonal and community levels thus provides quantitative 
measure for utilities to be gained with targeted interventions to improve attributes. This study 
is also meaningful to elicit changes in priorities using a same set of questions in a 
longitudinal design.   
 There are several limitations in this study. First, recruitment of participants was 
challenging and there was a high loss to follow-up; of these, 50% of LFU were due to 
relocation to outside of study areas. The baseline characteristics did not differ between those 
who were lost to follow up vs. retained in the study; however, we cannot determine whether 
these women may have different priorities regarding health or structural barriers to linkage to 
care. We tracked down mothers who missed regular clinic visits at 14 weeks and tried to 
capture them in the postpartum. Second, we could not verify the validity of self-reported 
adherence against other methods, such as pill counts or viral suppression data. Third, we 
asked participants to choose between statements with both positive and negative connotations 
in the same choice task. Therefore, our results can only infer which statements were 
perceived as best, and which were perceived as worst. However, we saw that the absolute 
rankings of preferences remained similar in the postpartum, supporting that our instrument 
likely had good face validity. The directionality of changes in the priorities across attributes 





  In summary, we have quantified maternal priorities for preventive therapies among 
HIV-positive pregnant women around the time of delivery. We demonstrate that trust in 
healthcare providers and medication benefits for infants and their own health are most highly 
prioritized in the antepartum and consistently in the postpartum.  However women may have 
more difficulty in adhering to therapies and coming to regular clinic visits in the postpartum.  
These study findings provide important insight to design patient-centered intervention and 
program for IPT delivery with the ultimate goal of improving the health of HIV-positive 
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Changing views of health promotion among HIV-positive pregnant 
women in South Africa before and after delivery: A choice experiment 
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 HIV-positive pregnant women who are initiated on life-long therapy have a high risk of 
becoming lost to follow-up (LFU) after delivery. We examined maternal motivation to take 
preventive therapies before and after delivery among pregnant women newly diagnosed with 
HIV. We enrolled pregnant women (≥18 years) with a recent HIV diagnosis (<6 months) at 14 
public primary health clinics in Matlosana, South Africa and followed them at 14 weeks 
postpartum. The motivation for taking preventive therapies was estimated using a conjoint 
analysis, with each respondent randomly receiving eight tasks comparing seven possible health 
benefits identified through literature reviews and key informant interviews. Data was analyzed 
using conditional logit and mixed logit (MXL) models in the antepartum vs. postpartum. 
Coefficients are reported with 95% confidence intervals and standard errors. 
Sixty-five women completed surveys at both enrollment and 14 weeks postpartum. All 
women were already started on ART while 21 (32%) were receiving IPT at enrollment. The mean 
CD4 count was 436 (± 246) cells/mm3.  In the antepartum, preventing HIV transmission to 
partners (coefficients (ß)=0.87, 95% CI: 0.64-1.11), followed by keeping them healthy for family 
(ß =0.75, 95% CI: 0.52-0.97), was the most prioritized motivator in conditional logistic 
regression. Such prioritization significantly decreased in the postpartum (p<0.001). While 
keeping high CD4 count was least prioritized in the antepartum (ß=0.19, 95% CI: -0.04, 0.43), it 
was most prioritized in the postpartum (ß=0.39, 95% CI 0.21-0.57). The results were similar in 
MXL models. We demonstrate that social motivation such as supporting family and preventing 
HIV transmission to partners may pose greater motivation for taking preventive therapies in the 
antepartum while individual health benefits are more prioritized in the postpartum. Changes in 
motivators need to be incorporated to deliver targeted health promotion messages among HIV-





It is estimated that about one-third of the 33 million HIV-positive individuals are co-
infected with Mycobacterium tuberculosis (TB) worldwide.86  Women at reproductive age have a 
higher HIV prevalence and are at the greatest risk of converting latent TB infection to active TB 
disease compared to men at similar age in sub-Saharan Africa.9,87  Pregnancy is an important 
gateway to the health system to provide routine screening tests including HIV and TB. It is during 
antenatal care (ANC) visits that many women first learn that they are infected with HIV. In South 
Africa, about 37% of women who attended ANC visits were HIV-positive and of these 23% 
reported any symptom of TB in 2011.12  The prevalence of TB in HIV-positive pregnant women 
is similar to that of the general population as 795/100,000 but they might be at 10-fold increased 
risk of active TB compared to HIV-uninfected pregnant women.88  
 
 The national guidelines for preventing mother-to-child transmission (PMTCT) and TB 
recommend that all pregnant and breastfeeding HIV-positive women are initiated on life-long 
antiretroviral therapy (ART) regardless of CD4 cell counts and if infected with TB, isoniazid 
preventive therapy (IPT) up to 36 months. ART not only prevents vertical HIV transmission but 
also achieves better long-term maternal health outcomes, and IPT can reduce the risk of 
developing TB among people living with HIV (PLWH) up to 60%.20,60,89  Nevertheless, 
implementation of these guidelines remain challenging. Many women may not be prepared for 
this long-term treatment commitment and fallen out of care after delivery. A recent study showed 
that up to half of women who initiated ART during pregnancy were lost to follow up six months 
after delivery in South Africa.8,7  Adherence rates to ART and IPT also significantly drop in the 
postpartum.18,90 In a meta-analysis done among sub-Sharan African studies, the proportion of 
women with adequate adherence for ART (>80%) reduced from 76% in the antepartum to 53% 
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during the postpartum period.17 Another study in Lesotho showed that 78.5% of HIV-positive 
women initiated IPT but 65% of these women completed the 6 month IPT.21  
 
Several factors have been associated with high loss to follow-up and lower adherence in 
postpartum period including late presence at ANC services, low social support, relocation during 
pregnancy, or lack of counseling and education.91–93 Among HIV-positive individuals, perceived 
benefits of ART as “life-giving” as well as treatment support from healthcare workers have been 
reported as important factors to adhere to ART.80,81  However, many pregnant women are often at 
an earlier stage of HIV disease without clinical symptoms but are initiated on ART during 
pregnancy to prevent HIV transmission to infants. Once they protect their babies from infection 
and stop breastfeeding, they are less likely motivated to remain in care.82 These factors emphasize 
the importance of understanding what motivates HIV-positive pregnant women to take ART and 
IPT around the time of delivery in order to provide targeted interventions thus to ensure better 
adherence and retention in care in long-term. In this study, we sought to quantitatively measure 
the relative importance of potential maternal motivators to take preventive therapies among 




5.3.1 Study participants 
This study was conducted from 14 primary care public health clinics in the Dr. Kenneth 
Kaunda health district in the North West province, South Africa from November 2014 to 
December 2015. It was nested within an ongoing cluster randomized trial in the same 14 clinics, 
which compares proportions with known TB infection status and IPT initiation among newly 
diagnosed HIV patients in clinics using two different diagnostic tests for latent TB infection.36,57 
  
 60 
Clinics were chosen to cover a range of patient volumes, urban vs rural setting, geography and 
clinic hours. Patients were eligible for enrollment if they were ≥18 years old, newly diagnosed 
with HIV in the preceding six months, and able to read either English, Xhosa, Setswana or Zulu. 
We sought to enroll all eligible patients during the study period. The study was approved by the 
institutional review boards at the Johns Hopkins School of Medicine and University of 
Witwatersrand. 
5.3.2 Study design 
We conducted a longitudinal survey using a conjoint analysis to elicit pregnant mothers’ 
motivation to take preventive therapies. Conjoint analysis refers to methods that elicit 
respondents’ preferences by allowing them to make choices over sets of hypothetical alternatives, 
where each alternative is described by several characteristics (i.e. attributes) related to health 
services or goods of interest.24,48 It has been applied to measuring preferences for a wide range of 
health applications including HIV prevention 94,95  and delivery services among women in rural 
settings.96 The advantage of conjoint analysis is that it allows to quantity the degree of 
preferences (i.e. preference weights) associated with different attributes.  
Through key informant interviews, literature review and expert consultations, we 
determined seven possible benefits of preventive therapies that may matter most to patients. The 
seven possible benefits of preventive therapies included (1) Keeps me healthy for my family (2) 
Keeps me from giving HIV to my partner (3) Keeps my HIV disease under control (4) Keeps me 
health from my family (5) Prevents me from getting sick from infections (6) Keeps me healthy 
and working (7) Prevents me from getting TB (Table 5.1). All conjoint tasks were forced choices 
(i.e. respondent could not opt out or choose neither option). An example of conjoint tasks is 
shown in Figure 5.1. In addition to completing the tasks, individuals were also asked to provide 
age, gender, ethnicity and other sociodemographic variables.  
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Table 5.1. List of seven potential motivations for taking preventive therapies 
Label Motivator  
Preventing HIV transmission Keeps me from giving HIV to my partner 
Overall health  Keeps me healthy and working 
Supporting family Keeps me healthy for my family 
High CD4 counts Keeps my CD4 high 
Disease control   Keeps my HIV disease under control 
Preventing infections  Prevents me from getting sick from infections 
Preventing TB Prevents me from getting TB 
 
We used a fractional factorial design where seven possible benefits were randomly 
allocated across eight questions per respondent.59  Each benefit was mutually exclusively 
presented in one of two options in an orthogonal array design. We used a main-effects orthogonal 
array, assuming that there are no interactions between these seven possible benefits.59,97  To 
reduce cognitive burden, each question was presented in a flashcard separately.  Each respondent 
was asked same questions both at enrollment and postpartum visits. 
 
We asked some people with HIV to describe the reasons why they drink medications to 
prevent disease.  In each question, I will show you what two people said, and ask you which 
person’s statements BEST describe the way YOU think about why to take preventive 
medications. 
Person 1: 
Keeps my CD4 high 
Keeps my HIV disease under control 
Keeps me healthy for my family 
Prevents me from getting TB 
  
□ I am more like this person 
Person 2: 
Keeps me healthy and working 
Prevents me from getting sick from 
infections 
Keeps me from giving HIV to my partner 
  
□ I am more like this person 
 
Figure 5.1. Example of a conjoint analysis task with seven motivations related to preventive 




5.3.3 Statistical analysis 
The data was analyzed using conditional logit and mixed logit models with fitting all 
motivators as explanatory variables to estimate relative utility or preference weight of each 
motivator in the antepartum and postpartum periods.26,98,55  Conditional logit model assumes that 
individuals have same underlying preferences and the random errors associated with choices are 
independent and identically distributed while mixed logit model assumes that individuals’ 
preferences may vary and can be described as continuous distribution. Mixed logit model also 
allows to control for intra-individual correlations due to repeated responses. Coefficients from 
both models can be interpreted as preference or utility weights associated with that attribute.55    
The primary outcome in the analysis was the choice between two sets of motivators in a 
given choice task. The independent variables were a set of seven dichotomous variables where 
each motivator presented on the right side was coded as one and the motivator not presented on 
the right ride was coded as zero. This coding scheme was applied since all seven benefits needed 
to be mutually exclusively presented in either side of choice sets. We fitted additional models 
with interaction terms between each motivator and being postpartum visits to explore whether 
participants had different priorities at enrollment and postpartum visits. Wald tests were used to 
test the statistical significance of the interaction terms. Coefficients are presented with standard 
errors and 95% confidence intervals. All analysis was performed in STATA 13.0.  
  
5.4 Results 
5.4.1 Participant characteristics 
A total of 72 people newly diagnosed with HIV were enrolled and completed the 
questionnaire. 65 women completed surveys at both baseline and follow-up visit (Table 5.2). At 
baseline, the mean age was 27 years (IQR:22-31 years) with average time since initial HIV 
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diagnosis of 51±75 days. The mean gestational week at enrollment was 18 (±7) weeks. All 
women were already started on ART, and the median CD4 count was 404 (IQR: 228-609) 
cells/mm3. About 30% (n=19) were on IPT at enrollment, and 85% (n=55) was not employed. All 
participants reported currently having a partner or spouse but 60% (n=38) was not living with 
partners.  
In the follow-up visits, >95% reported taking ART. Of 65 infants, 1 (1.5%) was 
confirmed as HIV-positive, 47 (72.3%) were HIV-negative, 4 (6.2%) had indeterminate status, 
and 13 (20.0%) did not receive PCR tests. Over 90% (n=61) of participants ever breastfed their 
infants, and 67% (n=41) were still breastfeeding. While 51.5% (n=33) reported that they 
received somewhat or a lot of support from friends and family to remember taking 
medications, 95.2% (n=60) did so from healthcare providers (p<0.001). About 97% (n=62) 
people of patients who were on ART reported that they were informed about side effect and 





Table 5.2. Characteristics of the study population at enrolment among 65 HIV-positive 
individuals, South Africa* 
N (%) N=65 
Age (years), Median (Q1, Q3) 27 (22, 31) 
Time since HIV diagnosis (days), Mean (± SD)  55 ± 51 
Gestational weeks, Mean (± SD) 18 ± 7 
CD4 cell count (cells/mm3),  
Median (Q1, Q3)‡ 
582 
404 (228, 609) 
Marital status  
Married 6 (9.4) 
Living with partner 20 (31.3) 
Not living with partner 38 (59.4) 
Employment status  
I work full time 5 ( 7.7) 
I work part time or piece jobs 5 ( 7.7) 
I am not employed 55 (84.6) 
Number of adults living in the household  
0-1 24 (36.9) 
2+ 41 (63.1) 
Number of children living in the household  
0-1 55 (84.6) 
2+ 10 (15.4) 
Transportation  
On foot 36 (55.4) 
Public taxi or bus 29 (44.6) 
TB treatment history  
Yes 4 (6.2) 
No 61 (93.8) 
Currently on IPT  
Yes 19 (29.2) 
No 46 (70.8) 
Currently on CPT  
Yes 4 (6.4) 
No 61 (93.6) 
 
*Pearson 2 test (discrete variables),  t-test (mean comparison for continuous variables) and 
Mann-Whitney test (median comparison for continuous variables) were used. 







5.4.2 Preference weights in antepartum vs. postpartum period 
Preference weights (i.e. utility) estimates for seven attributes are shown in Table 5.2. In 
the conditional logistic models, preventing HIV transmission had the highest coefficient (β=0.87, 
95% CI: 0.64-1.11), followed by supporting family (β=0.75, 95% CI: 0.52-0.97) where positive 
coefficients represent positive preferences for these motivators.  Keeping high CD4 counts 
showed the lowest coefficient (β=0.19, 95% CI: -0.04, 0.43) (Figure 5.2). In the postpartum 
period, the preference weights for most motivators significantly decreased. The coefficients for 
preventing HIV transmission and supporting family were 0.18 (95% CI: 0.00, 0.35) and 0.06 
(95% CI: -0.12, 0.24) in the postpartum, respectively. Keeping high CD4 counts had slightly 






Table 5.3 Coefficients from conditional logistic and mixed logit regressions in the antepartum vs. 
postpartum 


















Mean  0.87 (0.12) 0.18 (0.09) 1.73 (0.93) 0.19 (0.10) 
 SD  
___ 
 
1.64 (1.03) 0.15 (0.42) 
Overall health Mean  0.41 (0.12) 0.10 (0.09) 0.92 (0.53) 0.11 (0.10) 
 SD  
___ 
 
0.70 (0.77) 0.02 (0.38) 
Supporting family Mean  0.75 (0.11) 0.06 (0.09) 1.60 (0.85) 0.07 (0.10) 
 SD  
___ 
 
2.07 (1.20) 0.00 (0.18) 
High CD4 counts Mean  0.19 (0.12) 0.41 (0.09) 0.48 (0.31) 0.45 (0.11) 
 SD  
___ 
 
0.55 (0.91) 0.35 (0.21) 
Disease control   Mean  0.67 (0.12) 0.24 (0.09) 1.39 (0.77) 0.26 (0.11) 
 SD  
___ 
 
0.63 (0.84) 0.37 (0.20) 
Preventing 
infections 
Mean  0.40 (0.12) 0.05 (0.09) 0.85 (0.49) 0.05 (0.10) 
 SD  
___ 
 
1.07 (0.81) 0.31 (0.22) 





0.51 (0.88) 0.01 (0.30) 
  1 Mean β coefficients show estimated utility of each attribute, where positive coefficients 













      Figure 5.2. Preference weights estimated from conditional logit estimates for seven 
motivators to take preventive therapies among HIV-positive individuals in South Africa in 
the antepartum vs. postpartum period. The bar range represents 95% confidence interval for 
the mean preference weights. 
 
The results were consistent in mixed logit models. In the antepartum, preventing HIV 
transmission had the highest mean coefficient (β=1.73), followed by supporting family (β=1.60), 
while high CD4 counts had the lowest mean coefficient (β=0.48). When the mean coefficients of 
the motivators were compared, the magnitude of utility gain was almost three times higher for 
preventing HIV transmission compared to high CD4 counts in the antepartum. In the postpartum, 
the mean coefficients for preventing HIV transmission and supporting family decreased to 0.19 
and 0.07, respectively. Overall health, preventing infections and preventing TB had similar mean 








































When tested for the interaction with timing of visits, there were significant interactions 
between maternal motivators and timing of visits (Table 5.4). The preference weights for 
preventing HIV transmission and supporting family were 0.69 (±0.15) and 0.72 (±0.16) lower in 
the postpartum compared to in the antepartum, and the differences were statistically significant 
(p<0.001). 
 
Table 5.4. Coefficients from mixed logit regressions with interactions terms for postpartum 
visits among HIV-positive pregnant women (N=65)* 
Benefits related to preventive therapies Coefficient  Mixed Logit Estimates 
Preventing HIV transmission Mean  
0.91 (0.13)** 
 SD  0.30 (0.18) 
Overall health Mean  0.43 (0.13)** 
 SD  0.05 (0.91) 
Supporting family Mean  0.78 (0.13)** 
 SD  0.36 (0.16) 
High CD4 counts  Mean  0.21 (0.13) 
 SD  -0.06 (0.68) 
Disease control   Mean  0.69 (0.13)** 
 SD  0.02 (2.33) 
Preventing infections Mean  0.42 (0.13)** 
 SD  -0.05 (0.95) 
Preventing TB Mean  0.46 (0.13)** 
 
SD  0.00 (3.89) 
Interaction with time   
Time*Preventing HIV transmission Mean  -0.69 (0.15)** 
Time*Overall health Mean  -0.35 (0.16)** 
Time*Supporting family Mean  -0.72 (0.16)** 
Time*High CD4 counts Mean   0.20 (0.16) 
Time*Disease control   Mean  -0.40 (0.16)** 
Time*Preventing infections Mean  -0.36 (0.16)** 
Time*Preventing TB Mean  -0.27 (0.16) 






Pregnant women newly diagnosed with HIV faces the “triple burden” to accept that they 
are pregnant, newly diagnosed with HIV and need to make a life-long decision of initiating 
treatment.99 Using a conjoint analysis, we demonstrate that prioritization of maternal motivations 
to take preventive therapies may change in the antepartum vs. postpartum periods. We found that 
HIV-positive pregnant women had high level of social motivation such as preventing HIV 
transmission to partners or supporting family compared to motivation related to their own health 
during pregnancy. However, the extent of such prioritization subdued in the postpartum. This is 
similar to previous findings that women initiating ART during pregnancy are likely to prioritize 
infant’s health compared to their own health and have a strong motivation to take medications to 
prevent HIV transmission to their infants.82,99,100  Also providing care for children and family was 
considered as an important motivator for women to remain healthy.100 Our results underscore that 
while it is important to understand and support the social roles of HIV-positive pregnant women, 
more counseling needs to be provided with emphasis on the benefits of ART and IPT for maternal 
own health during antenatal care visits to ensure continued adherence to therapies.  
In the postpartum, there was no clear ranking among motivators although prioritization 
for preventing HIV transmission or supporting family substantially decreased. These results need 
to be interpreted with caution. Since everyone in the study needed to make choices per question 
(i.e. there was no opt-out option), the lack of clear ranking among different motivators does not 
imply that their motivations to take preventive therapies may have decreased in the postpartum. 
Instead, this suggests after delivering a healthy baby mothers may have extended their motivation 
towards protecting their own health. Other studies similarly showed that HIV-positive pregnant 
women perceived their own health as a motivator to continue on therapies101 and positive 
attitudes and perceived benefits towards treatment were reported as the facilitators for adherence 
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to ART and retention in care.80,102 In our study, most of participants had been on ART on average 
of 2 months at enrollment thus may have not fully perceived the benefits of ART. 
 It is interesting that the most significant motivator in the postpartum was keeping high 
CD4 counts. It is possible that the participants gained better understanding about clinical 
implication of CD4 counts through repeated HIV counseling and regular clinic visits over time. A 
study among HIV-positive pregnant women in South Africa showed that providing CD4 count 
results might have helped mothers take HIV diagnosis more seriously and resulted in improved 
retention in care and adherence to ART after delivery.99  Our study results highlight that 
counseling in the postpartum need to be geared towards promoting the benefits of ART and IPT 
for maternal health.  
 Other predictors of disengagement and/or poor adherence in the postpartum included 
non-disclosure of HIV status, feeling well, and inadequate knowledge about PMTCT.8,99 About 
80% of our participants disclosed their HIV status, and of those who knew their partners’ HIV 
status, 77% of partners were HIV-positive. We did not see any changes in estimates by disclosure 
status nor partners’ HIV status but this could be due to the small sample size. We fitted different 
models to estimate the associations. Mixed logit models have several advantages over conditional 
logit models as it allows the coefficients in the models to vary across individuals.103 We found 
that convergence of mixed logit took much longer than in estimating conditional logit models due 
to the small sample size.  
There are several limitations in our study. First, our study only considered benefits 
perceived at individual levels. Previous studies have shown that patient support is needed to be 
considered at multi-dimension including connectedness with health care providers and experience 
with care. Second, although our study results seem to reflect lack of maternal motivation in the 
postpartum period, however we cannot discount that mothers were less paying attention to the 
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surveys and choose more randomly in postnatal visits, resulting in overall lower scores. Third, 
our sample size of the study is quite small. In DCE, there is no standard sample size calculation.  
Lastly, interpretation of preference weights need caution. In our study, we did not have opt-out 
options thus participants had to make choices for each question. We used all positive statements 
thus the probability of choosing any one factor is naturally considered as greater than zero (i.e. 
better than choosing no factor).   
 
5.6 Conclusion 
In this study, we observed that prevention of HIV transmission and supporting family 
members were the most important motivators to take preventive therapies in the antepartum 
among HIV-positive pregnant women. Such prioritization subdued in the postpartum period, and 
keeping high CD4 count became a more important motivator. Incorporating the changes in 
preferences among HIV-positive women after delivery may enhance adherence and retention in 








Cost-effectiveness of isoniazid preventive therapy among HIV-positive 
pregnant women in South Africa  






To estimate the incremental cost-effectiveness of universal isoniazid preventive 
therapy (IPT) and test-directed treatment of latent tuberculosis infection (LTBI) screening 
among HIV-positive pregnant women in South Africa, we estimated the cost-effectiveness of 
12 months of IPT among HIV-positive pregnant in South Africa using a decision-analytic 
model from the health system perspective. We compared TST-directed IPT (performance of 
TST with delivery of IPT to women with positive results) with: 1) QuantiFERON-TB Gold 
In-Tube (QGIT)-directed IPT (performance of QGIT with delivery of IPT to women with 
positive results) and 2) Universal IPT (IPT offered to all HIV-positive women without 
screening for LTBI). Costs were measured empirically in 6 primary care public health clinics 
in Matlosana, South Africa in June-August 2016. Primary outcome was incremental cost-
effectiveness ratio (ICER), expressed in 2016 US dollars per disability-adjusted life-years 
(DALYs) averted. We used time horizon of 1 year for the analysis. DALYs and costs were 
discounted at 3% per year. We estimated that 36 of 1,000 pregnant women would develop 
TB over the course of one year in the absence of IPT. TST-directed IPT reduced this number 
to 32 versus 30 with QGIT-directed IPT and 26 with universal IPT. The incremental cost-
effectiveness ratio (ICER) of universal IPT, relative to TST-directed IPT, was $895/DALY 
averted while QGIT-directed IPT was dominated by universal IPT. ICER was most sensitive 
to the probability of developing TB, returning for TST reading and additional probability of 
IPT based on the positive results of LTBI screening. Providing IPT to all eligible pregnant 
HIV-positive pregnant women can be an effective strategy, especially when operational 





Of 37 million people are living with HIV in 2015, tuberculosis is the leading cause of 
death among HIV-positive individuals. For HIV-positive individuals with suppressed 
immune system, the risk of converting latent tuberculosis infection (LTBI) to active TB can 
be high as 15% per year without antiretroviral therapy (ART). In South Africa, where HIV 
and tuberculosis are on-going public health challenges, about 37% of women who attended 
antennal care visits were HIV-positive in 2014,12 and the prevalence of LTBI among females 
in reproductive age (15-49 years) is as high as 70%.11 HIV-positive pregnant women are at 
greatly increased risk of TB reactivation, as high as 10-fold (relative to HIV-negative 
women) in some populations.88  
 
Isoniazid preventive therapy (IPT) has been recommended as an important strategy as 
part of a comprehensive approach to end TB in endemic settings.104 IPT is most effective 
among individuals with LTBI – typically diagnosed with the tuberculin skin test (TST) or 
interferon-gamma release assays (IGRAs)90 – but testing for LTBI can cause some patients to 
be lost to follow-up. In South Africa, TST is recommended to determine the duration of IPT 
prescribed to people living with HIV (PLWH): 12 months if TST-positive or 36 months if 
TST is negative.38 However, TST poses operational challenges as tuberculin needs to be 
refrigerated and patients are required to come back for reading the results. Studies have 
shown that up to 50% of patients may not return for TST reading.35 
HIV-positive pregnant women may be a particularly relevant population for IPT 
delivery because antenatal care (ANC) visits represent a unique opportunity to screen for TB 
and provide preventive therapy. Maternal TB is a risk factor for maternal mortality, mother-
to-child HIV transmission, and infant adverse health outcomes.3–5 Thus it is crucial to prevent 
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reactivation of LTBI among HIV-positive pregnant women. However, only about 38% of 
eligible HIV-positive individuals were initiated on IPT in South Africa in 2015.1 While TST 
poses operational challenges, healthcare workers might be hesitant to initiate eligible patients 
on IPT without any LTBI screening.16,67 In this study, we sought to examine cost-
effectiveness of universal IPT and test-driven IPT strategies, considering the short-lived 
protection effect of IPT in high TB and HIV endemic settings with targeted intervention for 
HIV-positive pregnant women.   
 
6.3 Methods 
6.3.1 Study design, intervention, and population 
This was nested within an ongoing cluster randomized trial of TST versus QGIT in 
14 South African clinics.36,57 We conducted a cost-effectiveness analysis from the health 
system perspective in a hypothetical cohort of HIV-positive pregnant women in South Africa 
using decision analysis (Figure 1). We considered three strategies for providing IPT for 12 
months to adult HIV-positive pregnant women presenting for routine antenatal care at public 
primary health centers: 1) TST-directed IPT IPT (performance of TST with delivery of IPT to 
women with positive results); 2) QGIT-directed IPT (performance of QGIT with delivery of 
IPT to women with positive results); and 3) Universal IPT (IPT offered to all HIV-positive 
women without screening for LTBI).  We used duration of intervention at 1 year since it is 
the minimum duration of IPT recommended by the South African government when the 
results of TST are unavailable, and several studies have shown that IPT provision of 36 
months has greater protective effect on TB incidence compared to 6 months but given the 
high loss to follow-up after delivery among HIV-positive women, 36 months may not be 
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feasible.8 Also 12 months of IPT initiated during pregnancy would be continued to early 
post-partum when preventing TB has the greatest health effect for both mothers and infants. 
We used a proximal measure (TB cases and deaths averted). Primary model outcome was 
incremental cost-effectiveness (ICER) per disability-adjusted life-years (DALYs) averted.  
Costs of providing IPT under different strategies were empirically measured using an 
“ingredients” (bottom-up) approach in 6 primary care public health clinics in Matlosana 
subdistrict, South Africa in June 2016-January 2017. The bottom-up approach was used to 
identify all resources used to perform LTBI screening and IPT management and valued to 
develop a unit cost. These six clinics (3 clinics randomized to provide QGIT and 3 clinics 
continued to provide TST as a routine LTBIT screening) were chosen to represent wide 
ranges of geographic locations and volume of patients at clinics. We collected the costs of 
overheads, building space, equipment, staff, and consumables related to IPT initiation and 
management as well as diagnostics for TST and QGIT. All costs were adjusted for inflation 
using the consumer price index for South Africa and converted to US dollars using the 2016 
exchange rate (1US$=ZAR14.72 Rand).  
We used the combination of interviews, documentation reviews at subdistrict offices, 
and publically available information for products to calculate costs. Overheads costs and 
building space were allocated based on proportional space required and percentage of time 
devoted to LTBI screenings and IPT management. These information was obtained from time 
and motion studies, which counted the number and type of staff and estimated the time spent 
on TB screening and IPT prescription. Floor plans were obtained from all six clinics, and the 
values of building and facilities were estimated based on the average construction cost to 
build a public clinic per square meters.105 Equipment and furniture inventories were obtained 
from subdistricts offices and directly counted at clinics. Cost of training was calculated based 
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on the reported time spent on TST performance and IPT prescription during subdistrict or 
nurse-initiated and managed antiretroviral treatment (NIMART) trainings during the year 
prior to the interview. Current annual salaries of staff were obtained from subdistrict offices. 
Costs related to TB and DILI treatment was estimated from the published literature as well as 
from South African drug costs. For QGIT, we used the processing price of biosamples by the 
national health laboratory service (NHLS) and the QGIT kit price charged by a QIAGEN 
company. All costing was measured in Both DALYs and costs were discounted at 3%.  
6.3.2 Empiric costing 
Cost-effectiveness was measured as the incremental cost-effectiveness ratio (ICER) 
relative to TST-directed IPT (the baseline strategy) and expressed in units of 2016 US dollars 
per DALY averted. We also chose a time horizon of 1 year to analyze the health outcomes 
(TB and DILI cases) in the same year, followed by additional 6 months if TB treatment was 
needed. Recent studies in high TB burden settings showed that the protection from IPT was 
quickly lost within 6-12 months due to reactivation of persistent latent infection and 
reinfection from ongoing community transmission of LTBI106,107 so a time horizon of 1 year 
most likely reflect the effectiveness of IPT in a high TB burden setting in a conservative way.  
We assumed that 1 X-ray, 2 blood tests, and 2 liver functions tests were conducted for those 
with mild DILI, and 1 X-ray, 3 blood tests, and 3 liver functions tests for severe DILI with 1 
week of hospitalization.108  We also estimated the costs incurring to health system when the 
interventions would scale up to all eligible HIV-positive pregnant women per year in South 
Africa, which was estimated as 324,000 per year with birth rate of 1.8 million per year and 
30% HIV prevalence among those attending public antenatal care clinics in the South African 
health system.2 We did not include ART costs as part of intervention costs since we wanted 
to compare the incremental costs of TB screening and IPT only. We used WHO-suggested 
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country-specific willingness to pay (WTP) thresholds at $20,043, defined as three times of 
the national annual gross domestic product per capita in South Africa ($6,681) per DALY 





Figure 6.1. Model diagram of decision analysis model in the target population of HIV-positive 
pregnant women in high TB burden settings. In all three arms in (A), the subtrees continue to 




6.3.3 Epidemiologic, diagnosis and treatment parameters 
Parameters related to epidemiological outcomes were estimated from the scientific 
literature, giving preference to studies of HIV-positive pregnant women in South Africa, 
when available (Table 5.3).  Using the values estimated from our study and literature review, 
we assumed 50% of eligible patients initiated IPT with a range of values (22%-77%) in 
sensitivity analyses. We first assumed that the same proportion of eligible patients would 
initiate IPT if tested positive then ran sensitivity analyses that potentially more people 
compared to universal IPT arm would initiate IPT based on the results of TST or QGIT. 
There could be two mechanisms for this. Patients may actually prefer to have a test before 
initiating a treatment than no test at all.109 Studies have also shown that healthcare workers 
were concerned about induced drug resistance due to IPT and difficulty of ruling out active 
TB prior to IPT initiation.16 
We estimated DALYs among 1,000 HIV-positive pregnant women at age of 25 years, 
which is the median age of antenatal HIV-positive women presenting at public clinics in 
South Africa.2 We assumed that HIV-positive pregnant women experienced disability 
associated with HIV on ART,110 that those who initiated IPT had a defined risk of severe 
hepatotoxicity incurring additional costs and risk of mortality,111–114 and that HIV-positive 
pregnant women at age of 25 years had an average life expectancy of 33.9 years in the 
absence of TB.115 We assumed that every woman was on ART and that here was slight 
disability-associated with taking IPT, based on the disability weight for daily chronic 
medication and worry.110  DALYs were then calculated as the combination of years of life 
lost plus years of life with disability, with future outcomes discounted at 3% per year.  
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Mild toxicity was defined as ALT grade 3-4 and did not change duration of treatment 
or treatment efficacy. Severe DILI was defined as AST or ALT > five times the upper limit 
of normal level, leading to permanent discontinuation of treatment and 1 week of 
hospitalization. We assumed that severe DILI have occurred one month after IPT initiation 
on average. There are limited data on hepatotoxicity of IPT among HIV-positive pregnant 
women thus data from observational studies among pregnant women if available or outcomes 
from other randomized clinical trials was used.111–114 We assumed that incompletion of IPT 
occurred at 6 months after initiation on average and there was no protective effect of IPT 
after discontinuation. In our setting of high annual risk of TB re-infection, we conservatively 
assumed that the effect of IPT would only last while the patient was on IPT and impact on 
TB incidences. Patients developing active TB could be diagnosed and treated based on 
current case-detection and treatment rates in South Africa.1 We did not include any additional 
costs due to HIV or ART costs, assuming that all women were already diagnosed.  
6.3.4 Sensitivity and uncertainty analysis  
We performed a one-way sensitivity analysis, varying key parameters by ±75% when 
data on the range of parameters were limited. The outcomes were highly sensitive to 
proportion of additional initiation IPT in test-driven strategies and proportion of TST reading 
done thus we performed two-way sensitivity analysis varying these key parameters 
simultaneously. We also ran a scenario analysis where the probability of additional initiation 
of IPT has increased to 30%. Probabilistic sensitivity analysis (PSA) using Monte Carlo 
simulations was conducted to simultaneously vary all parameters across their ranges to 
generate 95% uncertainty ranges (UR) for outcome estimates of costs, DALYs, and cost-




6.3.5 Ethical considerations 
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Table 6.1. Epidemiologic, diagnostic and treatment parameters used in sensitivity analyses 




Low High Source 
Prevalence of LTBI 0.767 0.454 0.932 11 
Risk of TB with LTBI (per year)* 0.047 0.017 0 .074 4,116,117  
Relative risk to develop TB with IPT 0.38 0.06 0.57 6 
Proportion of IPT initiation without LTBI 
screening 
0.50 0.22 0.77 Study; 21 
Additional proportion of IPT initiation with 
LTBI screening 
0 0 0.5 Assumption 
Probability of return to TST reading 0.7 0.5 0.9 4,35  
Proportion of IPT completion† 0.645 0.47 0.88 21,90,118 
TST performance     
    Sensitivity (.10 mm) 0.60 0.45 0.67 4,119,120 
    Specificity (.10 mm) 0.91 0.68 1 119 
QGIT performance     
    Sensitivity 0.61 0.41 0.75 120,121 
    Specificity 0.90 0.675 1 120,121 
DILI and TB     
   IPT-related DILI‡ 0.03 0.002 0.15 111–114 
   Proportion of severe DILI 0.014 0.00005 0.029 111,112,114,122 
   Probability of death due to severe DILI 0.053 0.0001 0.1 112  
TB treatment  (%)      
   TB detection  0.64 0.48 0.80 1 
   TB mortality probability if untreated 0.50 0.375 0.625 1 
   TB treatment-related mortality 0.083 0.064 0.107 1,123 
Disability weights     
   Mild-IPT induced hepatotoxicity 0.15 0.05 0.3 
34    Severe IPT-induced hepatotoxicity‡ 0.6 0.1 0.9 
   Active TB treatment 0.1 0.01 0.25 
   Active TB (HIV+ co-infection) 0.408 0.274 0.549  
   HIV+ (receiving ART) 0.078 0.052 0.111 
   IPT 0.049 0.031 0.053  
   Life expectancy at initiation of ART** 33.9 31.5 36.5 115 
*We modeled progression to active TB within 1 year of model entry for decision analysis.  
†For those who did not complete 12-month IPT, we assumed that they received about 6 months of IPT, which 
resulted in a relative risk reduction of 0.31 in the base case (range 0.11-0.385).  
‡IPT-induced severe hepatotoxicity is defined as hepatitis grade 3 or higher.  
**Life expectancy at initiation of ART was calculated at median age of 25 years among HIV-positive 




*Data was based on the data collected from study clinics and local hospitals. 
  




Low High Source 
Cost of TST 2.19 1.64 2.74 
Study*; 33 
  Nursing staff time (application and 
reading)  0.45   
  Consumables and materials 
(gloves, syringes, needles, box for 
syringes) 1.14   
  Training unit cost  0.45   
  Overhead unit cost 0.06   
Cost of QGIT 54.38 40.79 63.97 Study 
   Nursing staff time  1.20    
   Consumables and materials 11.44    
   Lab cost 36.72    
   Sample transport cost 4.95    
   Overhead unit cost 0.07    
Costs of IPT     
   Isoniazid 300mg/day (monthly)  0.90 0.70 1.10  Study 
   Initial consultation 1.89 1.40 2.40  Study 
Follow-up outpatient consultation 
per visit 1.73 1.30 2.20  Study 
Total cost of IPT treatment (12 
months) 
31.72 11.00 64.90 Calculated; 31 
Cost related to DILI and TB 
treatment costs    
 
   Blood count tests 9.48 2.76 10.86 124,125 
   Liver function test 8.92 4.76 27.68 124–126 
   Sputum test 2.00 1.03 2.20 124,127,128 
   Chest Xray 18.91 5.03 23.46 124,127,128 
   Outpatient follow-up at tertiary 
hospital 
18.42 6.73 39.71 31,129 
   Hospitalization per diem 109.38 45.60 126.64 Study; 31,129 





6.4.1 Cost and cost-effectiveness of IPT provision and LTBI diagnostics 
The average total cost per patient in universal IPT, QGIT-directed IPT, or TST-
directed IPT arms was $23.38, $67.50, and $12.70, respectively (Table 3). Providing IPT to 
all HIV-positive pregnant women had the highest cost for IPT ($12.97) and IPT-related DILI 
treatment costs ($6.99) but had slightly lower cost for TB treatment ($2.48) than providing 
IPT to women with positive results of QGIT or TST. The median costs per 1000 patients 
including diagnostic, IPT, IPT-related DILI treatment and TB treatment were $23,383 (IQR 
$20,480-$26,479) in universal IPT, $76,584 (IQR $65,486-$94,698) in QGIT-directed IPT 
and $12,069 (IQR $10,803-$13,653) in TST-directed IPT, respectively. To scale up the 
intervention to all HIV-positive pregnant women in South Africa of approximately 324,000 
would cost about $7.6, $5.1 and $25.8 million (Table 6.4). Compared to universal IPT arm, 
QGIT-directed arm was absolutely dominated.  
 
Table 6.3 Average total cost per patient 
 Universal IPT IPT with TST 
IPT with 
QGIT 
Diagnostic 0.94 2.94 54.84 
LTBI treatment  12.97 4.36 6.37 
IPT-related DILI 6.99 2.35 3.43 
TB treatment 2.48 3.04 2.86 
Average total cost per patient  
(2016 US$) 






Table 6.4 Expected costs, DALYs averted, and incremental cost-effectiveness 









TST 12,648 31.8 7.5 174 
 
Universal IPT 23,382 25.9 6.4 162  
Incremental universal IPT 
vs. TST 
10,734 5.9 1.1 -12 895 
IPT with QGIT 67,504 29.9 7.1 168  
Incremental QGIT vs. TST 54,856 1.9 0.4 -6 9143 
*324,000 births per year estimated to occur among HIV-positive pregnant women  




Among 1,000 women in the cohort, 767 were assumed to have LTBI, of whom 36 
would develop reactivation of TB and 8 would die of TB in the absence of IPT. In the TST-
directed IPT strategy, 168 (16.8%) of 1,000 women were assumed to receive IPT, reducing 
the number of TB cases to 31.8 and TB deaths to 7.5. Of these, 7.3 patients without LTBI 
would be started on IPT due to false-positive results, of whom 0.3 patient was assumed to 
experience mild or severe DILI and 0.01 to die due to DILI. Under the universal IPT strategy, 
500 (50.0%) of 1,000 women were assumed to receive IPT, reducing the number of TB cases 
to 25.9 and TB deaths to 6.5 patients. 116 patients without LTBI would be started on IPT, of 
whom 5.1 patient was assumed to experience mild or severe DILI and 0.09 to die due to 
DILI. The incremental cost-effective ratio (ICER) was $895/DALY averted in universal IPT 
and $9,143/DALY averted in QGIT-driven IPT.  
 
6.4.2 Sensitivity analyses  
Parameters that were found to have the greatest effect on the incremental cost-
effectiveness of universal IPT relative to TST-directed IPT in one-way sensitivity analysis 
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are shown in Figure 5.2. Specifically, the ICER was most sensitive to estimates of the 
probability of progression from LTBI to active TB. When the risk of progression to active TB 
increased to 7.4%, the ICER increased to $32,412 per DALY averted. ICERs were also 
sensitive to prevalence of LTBI. When the risk of reactivation fell below 1.8%, universal IPT 
became less effective than TST-directed IPT because the risk of side effects outweighed the 
benefit of IPT. When prevalence of was low as 45.4%, universal IPT also became less 
effective compared to TST-directed IPT.  
 Results of PSA are shown in Figure 5.3, with median ICERs of $985/DALY averted 
(95% CI $235-$14,988) based on 10,000 Monte Carlo simulations of the model. The cost-
acceptability curve is shown in Figure 5.4. At a WTP threshold of US$20,043/DALY averted 
in the context of South Africa, 88% of simulations favored the universal IPT arm. The QGIT 
arm had the mean ICERs of $9,830/DALY averted (95% CI $5,048-$30,627) compared to 






Figure 6.2. Tornado diagram for one-way sensitivity analysis for incremental cost-effectiveness 
ratio per DALY averted, comparing universal IPT arm vs. TST arm. Red and blue bars represent 
the highest and lowest values in the range in each variable.   
 
 
Figure 6.3. Tornado diagram for one-way sensitivity analysis for incremental cost-effectiveness 
ratio per DALY averted, comparing QGIT arm vs. TST arm. Red and blue bars represent the 
highest and lowest values in the range in each variable.   
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Figure 6.4. Point diagram resulting from the probabilistic sensitivity analysis, comparing 
universal IPT arm vs. TST arm under 10,000 monte carlo simulation 
 
6.4.3 Impact of TST reading and proportion of additional initiation of IPT  
 We ran several sensitivity analyses for the performance of TST with IPT given to 
positive TST results. First, when the probability of additional IPT initiation in TST-driven 
IPT arm increased to 30%, the ICER increased to $1,025/DALY averted in universal IPT, 
compared to TST-driven IPT. Figure 5.5 shows ICERs in the two-way sensitivity analyses 
comparing universal IPT vs. TST-directed IPT under different probability of TST reading 
done and additional IPT initiation in TST-directed IPT. When the probability of TST reading 
done is low (<50%), universal IPT had the ICER less than $1,000/DALY averted regardless 






















Incremental Effectiveness (DALY averted)
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reading done and additional initiation of IPT increase, the ICER increased further and could 
result in cost-saving for TST-driven IPT strategy.    
 
 
Figure 6.5. Two-way sensitivity analysis diagram comparing probability of LTBI and probability 
of starting IPT when probability of TST being read is at 0.90 across all arms  
 
 
Figure 6.6. Cost-acceptability curve for universal IPT, TST-directed IPT, and QGIT-directed IPT 
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 Usage of TST has been used as a traditional way to test LTBI in resource-limited 
settings. Our results suggest that universal IPT for 12 months, compared to TST-driven IPT 
strategy in which IPT is only provided to TST-positive patients, has ICER of $895/DALY 
averted in high TB and HIV burden settings with potentially rapid loss of protective effect 
from IPT upon cessation of IPT. We have taken a conservative approach where the protective 
effect of IPT would last only for 12 months. Several sensitivity analyses were additionally 
performed and showed that the incremental effectiveness with additional cost spent on IPT 
might differ significantly, depending on the context of settings. With slightly higher DALY 
due to IPT, there are also net gains by preventing TB cases and TB deaths.  When compared 
to universal IPT arm, QGIT-directed arm was absolutely dominated.  
This study is meaningful in several ways. First, we empirically measured the costs. 
The cost of TST was quite low compared to previously reported values. We did not account 
the impact of patient volumes on the cost of tuberculin; each vial contains 10 tests and needs 
to be refrigerated and used within one month upon opening. Thus low TST performance may 
increase the cost of TST. Although professional nurses were provided training on TB and 
HIV screening and management on a regular basis by the district office, training time spent 
on TB screening and IPT performance was very low. In the six clinics, the number of staff 
who could perform TST quite varied. In some clinics, only TB nurses were performing TST 
while any professional nurse could perform TST in other clinics.  
Second, we estimated the cost-effectiveness of IPT HIV-positive pregnant women 
and estimated the cost and effectiveness for scaling up this intervention to all potentially 
available women in the context of South Africa with high HIV burden. A recent study in 
India reported that IPT regardless of CD4 cell count among HIV-positive pregnant women 
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was cost-effective compared to no IPT, which is the standard of care in India, and also found 
that providing IPT regardless of IPT was cost-effective compared to TST-driven strategies 
129. However, this study assumed the protection of IPT would last over a person’s life time 
horizon of 20 years. Second, several studies examined cost-effectiveness of IPT among 
PLWH in low- or middle TB-burden countries with a rather long time horizon for analysis of 
20 years or longer 29,31,126 but few studies were conducted in high endemic settings for both 
TB and HIV. As studies have continuously shown that the effect of IPT is quite limited upon 
cessation of IPT in high TB burden settings due to reactivation or reinfection, shorter time 
frame for analysis seems to be more appropriate. In this study, when a 1 year of time horizon 
was considered, universal IPT was still considered cost-effective.  
 Many previous studies have shown that providing IPT is cost-effective to avert TB 
cases, especially among HIV-positive individuals.29,33,129 Given the evidence of effectiveness 
of IPT, the South African government originally recommended to initiate IPT regardless of 
TST in 2011. However, the re-introduction of TST in the new guideline in 2013 without 
sufficient communication and training in local hospitals have been considered as a barrier to 
IPT implementation.16  
In the case scenario of 30% additional initiation of TST, we found that the ICER in 
universal IPT was $1,025/DALY averted but when majority of people placed with TST come 
back, the probability of additional IPT initiation among patients with TST-positive results is 
critical in terms of cost-effectiveness. However, when many patients may not come back for 
TST reading, even at the best scenario of initiating IPT for 100% based on TST-positive 
results compared to 50% IPT initiation in universal IPT arm, the highest ICER with 50% of 
TST reading done would be $1,107/DALY averted. Thus when there are operational 
challenges of TST, universal IPT could be an effective strategy given resources required.   
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There are several limitations in this study. Although we found that the intervention was 
cost-effective compared to the conventional GDP threshold, different thresholds can be 
applied to determine cost-effectiveness and may not apply to other interventions. Also, we 
assumed that every pregnant woman was on ART as observed in our study as well as in the 
national South African health report.105 However, maternal ART coverage may decrease in 
the postpartum period and other settings may have lower ART coverage among pregnant 
women. We considered the effect of IPT separately but there could be synergetic effect 
between ART and IPT to reduce TB incidence.130 We also assumed that the efficacy of IPT is 
similar in antepartum and postpartum period and people won’t be lost to follow up in the 
postpartum period. However, many studies have shown that pregnant women are less likely 
to be retained in the care after delivering a healthy baby. We assumed that the same 
percentage of additional people would be initiated on IPT in the QGIT arm but this 
assumption may not be valid. Currently, the trial is on-going whether QGIT linked to routine 
CD4 test counting would allow more people to be initiated on IPT in the same clinics. 
 
6.6 Conclusion 
 In this study, we showed that universal IPT can be an effective strategy for IPT provision, 
especially when operational challenges of TST performance is substantial. As IPT is 
considered as an important strategy to end TB, universal IPT should be considered as a 
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CHAPTER 7  
         Conclusion  
 
7.1 Summary of dissertation   
 In this dissertation, we examined the changes in priorities related to preventive 
therapies among HIV-positive pregnant women in South Africa using conjoint analysis and 
best-worst scaling methods. Mothers prioritized trust in healthcare providers, followed by 
living a long life. Fear of unintended disclosure of HIV status due to daily pill take was least 
prioritized. The overall ranking of attributes was similar by IPT initiation at enrollment. 
When priorities were compared before and after delivery, mothers reported that they had 
significantly greater difficulty in taking medications on a daily basis in the postpartum 
period. On the other hand, maternal motivation to take preventive therapies was most 
prioritized for preventing HIV transmission to a partner or keeping healthy for family, 
compared to other motivators related to their own health in the antepartum. However, the 
extent of such prioritization subdued in the postpartum and keeping high CD4 count was 
considered as the most important motivator in the postpartum. We also found that universal 
IPT can be an effective strategy, especially if application and reading of TST poses 




7.2 Limitations  
There are many limitations in this thesis work. First, the study had about 25% loss to 
follow-up in the overall cohort; in addition, the DCE instrument (Chapter 5) was added into 
the study questionnaire after the study enrollment was half completed thus the sample size at 
baseline was quite small. When people lost to follow up were compared to those included in 
the analysis, we observed no systematic difference. We tried to contact and track down 
mothers who missed scheduled clinic visits and complete follow-up visits as needed. 
However, about one-third of those lost to follow up relocated to different location and 
another one-third could not be reached further. Those who were potentially disengaged from 
the care may have had different priorities compared to the ones included in the analysis. 
Secondly, we tried to enroll all eligible participants at the study clinics but due to limited 
number of study staff we could have missed some participants presented at clinics. Third, 
although the instrument development was based on the qualitative interviews which were 
conducted in the same 14 clinics, only few pregnant women were included as part of the 
interviews. We did perform literature reviews to select the motivators mostly relevant to 
maternal decisions but there could be other motivators not included in this study. Fourth, we 
did not have the data on viral suppression in the postpartum and the self-reported adherence 
could have been overstated. Also we did not capture the duration or completion of IPT 
among those who were prescribed to take INH. The proportion of people receiving IPT was 
low in the both antepartum and postpartum periods thus we could not statistically compare 





7.3 Public health implications 
This study provides important insight into the patient-centered delivery of preventive 
therapies among HIV-positive pregnant women in South Africa and potentially in other high 
HIV and TB burden settings. Although HIV-positive women after delivery prioritize 
attributes related to infants’ health, they have high perceived benefits of medications for their 
own health in the postpartum period. Similarly, pregnant women newly diagnosed with HIV 
might be more motivated to take therapies for partners or family members in the antepartum, 
such relative importance decreases in the postpartum and health promotion messages for high 
CD4 counts or maternal health benefits would be potentially well received. Our study results 
suggest that if IPT is provided to HIV-positive pregnant women with adequate counseling 
and support, it is likely that the uptake of IPT would be improved both in the antepartum and 
postpartum periods. Targeted counseling and interventions to emphasize the benefits of ART 
and IPT in the postpartum could be important.  We demonstrate that application of stated 
preferences methods could be an alternate way to elicit patients’ preferences in other resource 
limited settings. Finally, as IPT is considered as an important strategy to end TB, universal 
IPT can be a potential option to maximize the benefits of IPT at population level especially in 
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